A catalog of associations between rare coding variants and COVID-19 outcomes

J. A. Kosmicki[1†], J. E. Horowitz[1†], N. Banerjee[1], R. Lanche[1], A. Marcketta[1], E. Maxwell[1], X. Bai[1], D. Sun[1], J. D. Backman[1], D. Sharma[1], H. M. Kang[1], C. O'Dushlaine[1], A. Yadav[1], A. J. Mansfield[1], A. H. Li[1], K. Watanabe[1], L. Gurski[1], S. E. McCarthy[1], A. E. Locke[1], S. Khalid[1], S. O'Keeffe[1], J. Mbatchou[1], O. Chazara[2], Y. Huang[3], E. Kvikstad[5], A. O'Neill[2], P. Nioi[4], M. M. Parker[4], S. Petrovski[2], H. Runz[3], J. D. Szustakowski[5], Q. Wang[2], E. Wong[6], A. Cordova-Palomera[6], E. N. Smith[6], S. Szalma[6], X. Zheng[7], S. Esmaeeli[7], J. W. Davis[7], Y-P. Lai[8], X. Chen[8], A. E. Justice[9], J. B. Leader[9], T. Mirshahi[9], D. J. Carey[9], A. Verma[10], G. Sirugo[10], M. D. Ritchie[10], D. J. Rader[10], G. Povysil[11], D. B. Goldstein[11,12], K. Kiryluk[11,13], E. Pairo-Castineira[14,15], K. Rawlik[14], D. Pasko[16], S. Walker[16], A. Meynert[15], A. Kousathanas[16], L. Moutsianas[16], A. Tenesa[14,15,17], M. Caulfield[16,18], R. Scott[16,19], J. F. Wilson[15,17], J. K. Baillie[14,15,20], G. Butler-Laporte[21,22], T. Nakanishi[21,23-25], M. Lathrop[23,26], J.B. Richards[21-23,27], Regeneron Genetics Center*, UKB Exome Sequencing Consortium*, M. Jones[1], S. Balasubramanian[1], W. Salerno[1], A. R. Shuldiner[1], J. Marchini[1], J. D. Overton[1], L. Habegger[1], M. N. Cantor[1], J. G. Reid[1], A. Baras[1‡], G. R. Abecasis[1‡], M. A. Ferreira[1‡]

From:

[1]Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA

[2]Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK

[3]Biogen, 300 Binney St, Cambridge, MA 02142, USA

[4]Alnylam Pharmaceuticals, 675 West Kendall St, Cambridge, MA 02142, USA

[5]Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA

[6]Takeda California Inc., 9625 Towne Centre Dr, San Diego, CA 92121, USA

24 [7]AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA

25 [8]Pfizer, Inc., 1 Portland Street, Cambridge MA 02139, USA

26 [9]Geisinger, Danville, PA, 17822, USA

27 [10]Department of Genetics, Perelman School of Medicine, University of Pennsylvania,

28 Philadelphia, PA, 19104, USA

29 [11]Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY

30 10032, USA

31 [12]Department of Genetics & Development, Columbia University, New York, NY 10032, USA

32 [13]Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons,

33 Columbia University, New York, NY 10032, USA

34 [14]Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK

35 [15]MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of

36 Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

37 [16]Genomics England, London EC1M 6BQ, UK

38 [17]Centre for Global Health Research, Usher Institute of Population Health Sciences and

39 Informatics, Teviot Place, Edinburgh EH8 9AG, UK

40 [18]William Harvey Research Institute, Barts and the London School of Medicine and Dentistry,

41 Queen Mary University of London, London EC1M 6BQ, UK

42 [19]Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK

43 [20]Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16

44 5SA, UK

45 [21]Lady Davis Institute, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada

46 [22]Department of Epidemiology, Biostatistics and Occupational Health, McGill University,

47 Montréal, Québec H3A 0G4, Canada

48 [23]Department of Human Genetics, McGill University, Montréal, Québec H3A 0G4, Canada

49 [24]Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate School of

50 Medicine, Kyoto University, Kyoto 606-8501, Japan

51 [25]Research Fellow, Japan Society for the Promotion of Science

52 [26]Canadian Centre for Computational Genomics, McGill University, Montréal, Québec H3A

53 0G4, Canada

54 [27]Department of Twins Research, King's College London, London WC2R 2LS, UK

55

56 *A complete list of investigators is provided in the Supplementary Appendix.

57 †J. A. Kosmicki and J. E. Horowitz contributed equally to this manuscript.

58 ‡A. Baras, G. R. Abecasis and M. A. Ferreira jointly supervised this work.

59 Correspondence to: manuel.ferreira@regeneron.com and goncalo.abecasis@regeneron.com

60 **This research has been conducted using the UK Biobank Resource (Project 26041)**

ABSTRACT

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease-19 (COVID-19), a respiratory illness that can result in hospitalization or death. We investigated associations between rare genetic variants and seven COVID-19 outcomes in 543,213 individuals, including 8,248 with COVID-19. After accounting for multiple testing, we did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 14 interferon pathway genes in which rare deleterious variants have been reported in severe COVID-19 patients; (ii) 167 genes located in COVID-19 GWAS risk loci; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential. Our analyses indicate there are no significant associations with rare protein-coding variants with detectable effect sizes at our current sample sizes. Analyses will be updated as additional data become available, with results publicly browsable at https://rgc-covid19.regeneron.com.

74 **MAIN TEXT**

75 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] causes coronavirus
76 disease 2019 (COVID-19) [2]. COVID-19 ranges in clinical presentation from asymptomatic
77 infection to flu-like illness with respiratory failure, hyperactive immune responses and death [3-
78 5]. It is currently estimated that SARS-CoV-2 has infected >100 million individuals and has been
79 attributed to >2 million recorded deaths worldwide. Known risk factors for severe disease include
80 male sex, older age, ancestry, obesity and underlying cardiovascular, renal, and respiratory
81 diseases [6-9], among others.

82

83 Since the start of the SARS-CoV-2 pandemic, host genetic analysis of common genetic variation
84 among SARS-CoV-2 patients have identified at least nine genome-wide significant loci that
85 modulate COVID-19 susceptibility and severity, including variants in/near *LZTFL1*, *IFNAR2*,
86 *DPP9* and the *HLA* region [10-13]. However, to date, there has been no assessment of the
87 contribution of rare genetic variation to COVID-19 disease susceptibility or severity through large
88 population-based exome-wide association analyses.

89

90 To identify rare variants (RVs, minor allele frequency [MAF]<1%) associated with COVID-19
91 susceptibility and severity, we generated exome-wide sequencing data for 543,213 individuals
92 from three studies (Geisinger Health System [GHS], Penn Medicine BioBank [PMBB] and UK
93 Biobank [UKB]) and three ancestries (African, European and South Asian) (**Supplementary**
94 **Table 1**). Of these, 8,248 had COVID-19, and among those 2,085 (25.28%) were hospitalized and
95 590 (7.15%) had severe disease (i.e. requiring ventilation or resulting in death; **Supplementary**
96 **Table 2**). Using these data, we tested the association between RVs and seven COVID-19

97 outcomes: five related to disease susceptibility and two related to disease severity among COVID-
98 19 cases (**Supplementary Table 3**). In a separate paper [13], we used these same phenotypes to
99 validate the association with common risk variants reported in previous COVID-19 GWAS[10-
100 12], thus demonstrating that our phenotypes are calibrated with those used in other studies.
101
102 For each phenotype, exome-wide association analyses were performed separately in each study
103 and ancestry using REGENIE[14], testing single RVs (~7 million) and a burden of RVs in 18,886
104 protein-coding genes. The genomic inflation factor (λ_{GC}) for RVs was often <1 in individual
105 studies, caused by a large proportion of variants having a minor allele count (MAC) of 0 in cases
106 (**Supplementary Table 4**). In meta-analyses across studies and ancestries, we found no RV
107 associations at a conservative $P<9.6\text{x}10^{-10}$, which corresponds to a Bonferroni correction for the
108 number of variants and traits tested. The most significant associations with RVs are listed in **Table**
109 **1**, all observed with our COVID-19 hospitalization phenotype (2,085 hospitalized cases vs.
110 534,965 COVID-19 negative or unknown controls). Of these, we highlight an association with an
111 RV in the promoter of *EEF2* (rs532051930:A, MAF=0.003%, OR=93.9, 95% CI 20.3-434.5,
112 $P=6.2\text{x}10^{-9}$; **Supplementary Figure 1A**), a translation elongation factor which plays a key role in
113 viral replication[15, 16].
114
115 Despite not reaching our threshold for genome-wide significance, we highlight the association
116 with *EEF2* because: (i) it was supported by two independent studies (**Supplementary Figure 1B**);
117 (ii) five additional RVs in the 89 bp promoter of *EEF2* (out of 50 tested) had an independent and
118 directionally-consistent predisposing association with the same hospitalization phenotype
119 ($P<0.05$; **Supplementary Table 5**); (iii) rs532051930 is predicted by DeepSEA [17] to be a

120 regulatory variant and to disrupt binding of several transcription factors, including GABP, which
121 has been linked to RV-induced aberrant gene expression [18]; (iv) rs532051930 is located at the
122 peak of the transcription initiation region for *EEF2* (**Supplementary Figure 1C**) [19], suggesting
123 that it might affect RNA polymerase II binding; and (v) among a subset of 1,988 individuals with
124 available RNA-seq data from liver tissue, the only individual who was a carrier for rs532051930:A
125 had the second highest expression of *EEF2* (**Supplementary Figure 1D**). These results raise the
126 possibility that rs532051930 and potentially other promoter RVs increase *EEF2* transcription and,
127 consequently, increase risk of hospitalization due to SARS-CoV-2 infection.
128
129 Given these supporting observations and the established role of *EEF2* in viral replication, we
130 studied the genetic association with rs532051930 in greater detail, to understand if it was likely to
131 be a true-positive association. First, we reviewed sequencing reads for all 26 carriers of this variant,
132 to visually validate the heterozygote genotype call produced by the calling algorithm. Sequencing
133 reads were consistent with a heterozygote call for all 26 individuals. Second, we determined if the
134 association with this rare variant was robust to the association test used (**Supplementary Table**
135 **6**). A Firth test applied to a joint analysis of data across the two studies, adjusting for study specific
136 covariates as an offset, resulted in P=5.5x10^{-8}. Similar results were obtained by: (i) an
137 approximation to this approach, which combines log-likelihood curves calculated at a grid of
138 values with the Firth penalty, applied using approximate derivatives; (ii) a P-value-based meta-
139 analysis, for which there is evidence of better type-I error control [20]; and (iii) the BinomiRare
140 test [21], which uses a test statistic based on allele counts in cases only, adjusts for covariates and
141 combines data across studies. We also applied tests without covariates and these uniformly led to
142 less significant associations, but this is expected since the covariates explain variation in the

143 phenotype. Third, we attempted to replicate this association by querying whether this variant was
144 present in an additional 4,341 COVID-19 cases with exome- or whole-genome sequence data
145 generated as part of the GenOMICC (n=2,969) [11], Columbia University COVID-19 Biobank
146 (n=1,152) and Biobanque Quebec (n=220) [22] studies. We found no carriers for this variant in
147 these additional COVID-19 cases (**Supplementary Table 7**). Given these findings, we conclude
148 that it is not certain that there is a true association between rs532051930 and COVID-19 risk,
149 illustrating the importance of replication.
150
151 Next, we addressed the possibility that associations with protein-coding RVs might help pinpoint
152 target genes of common risk variants identified in GWAS of COVID-19. To this end, we focused
153 on 167 genes located within 500 kb of the nine common variants associated with COVID-19
154 hospitalization in a separate analysis [13]. Of the 334 gene burden tests performed (167 genes x 2
155 burden tests), which considered both pLoF variants alone (M1 burden test) or pLoF plus
156 deleterious missense variants (M3 burden test), 17 had a nominally significant association with the
157 same COVID-19 hospitalization phenotype (**Supplementary Table 6**). Of these, burden tests for
158 one gene – *CHAF1A* (OR=25 for the M1 burden test, 95% CI 4.9-128.5, P=1.0x10^{-4}) – remained
159 borderline significant after correcting for the 334 tests performed (P<0.05/334=1.5x10^{-4}).
160 *CHAF1A* is located 317 kb from the lead common variant at locus 19p13.3 [13], is highly
161 expressed in EBV-transformed B-cells [23] and encodes a component of the chromatin assembling
162 factor complex that affects cell differentiation, including the differentiation of pre-B cells into B-
163 cells and macrophages [24].
164

165 We then examined the association with 14 genes in the interferon pathway, given recent reports
166 that deleterious RVs in these genes may be implicated in severe clinical outcomes [25, 26]. Given
167 the larger sample size in our studies, we examined whether there was any evidence for association
168 between the COVID-19 hospitalization phenotype (2,085 cases vs. 534,965 controls) and the
169 burden of rare (MAF<0.1%) pLoF variants (M1 burden test) or pLoF plus deleterious missense
170 variants (M3 burden test) in these 14 genes, three of which are located within 500 kb of a COVID-
171 19 GWAS risk variant (*IFNAR1*, *IFNAR2* and *TICAM1*). Of the 14 genes, only two genes had a
172 nominal significant association: *STAT2* and *TLR7* (**Table 2**). However, neither remained
173 significant after correcting for the 28 tests performed (both with P>0.05/28=0.0018). Further, these
174 results were unchanged when testing COVID-19 severe cases (N=590), or when restricting the
175 burden tests to include variants with a MAF<1% or singleton variants (**Supplementary Table 7**).
176 Therefore, as recently reported by others [22], we found no evidence for an association between
177 RVs in these 14 interferon signaling genes and risk of COVID-19.
178
179 Lastly, we performed the same analysis for an additional 32 genes that are involved in the etiology
180 of SARS-CoV-2 infection (*ACE2, TMPRSS2*), encode therapeutic targets for COVID-19 obtained
181 through ClinicalTrials.gov (*e.g. IL6R, JAK1*) or have been implicated in other immune or
182 infectious diseases through GWAS (*e.g. IL33*). After correcting for multiple testing, there were
183 also no significant associations with a burden of deleterious RVs for this group of COVID-19
184 therapeutic target genes (**Supplementary Table 8**).
185
186 In summary, we provide a catalog of RV associations with COVID-19 outcomes based on exome-
187 sequence data, capturing genetic variation not assayed by array genotyping or imputation. We did

188 not find any convincing associations with current sample sizes, but will continue to expand our

189 analyses and update results periodically at https://rgc-covid19.regeneron.com.

190 **METHODS**

191

192 **Participating Studies**

193 *Geisinger Health System (GHS).* The GHS MyCode Community Health Initiative study has been
194 described previously [27]. Briefly, the GHS study is a health system-based cohort from central and
195 eastern Pennsylvania (USA) with ongoing recruitment since 2006. A subset of 144,182 MyCode
196 participants sequenced as part of the GHS-Regeneron Genetics Center DiscovEHR partnership
197 were included in this study. Information on COVID-19 outcomes were obtained through GHS's
198 COVID-19 registry. Patients were identified as eligible for the registry based on relevant lab results
199 and ICD-10 diagnosis codes; patient charts were then reviewed to confirm COVID-19 diagnoses.
200 The registry contains data on outcomes, comorbidities, medications, supplemental oxygen use and
201 ICU admissions.

202

203 *Penn Medicine BioBank (PMBB) study*. PMBB study participants are recruited through the
204 University of Pennsylvania Health System, which enrolls participants during hospital or clinic
205 visits. Participants donate blood or tissue and allow access to EHR information[28]. The PMBB
206 COVID-19 registry consists of patients who have positive qPCR testing for SARS-COV-2. We
207 then used electronic health records to classify COVID-19 patients into hospitalized and severe
208 (ventilation or death) categories.

209

210 *UK Biobank (UKB) study*. We studied the host genetics of SARS-CoV-2 infection in participants
211 of the UK Biobank study, which took place between 2006 and 2010 and includes approximately
212 500,000 adults aged 40-69 at recruitment. In collaboration with UK health authorities, the UK

213 Biobank has made available regular updates on COVID-19 status for all participants, including
214 results from four main data types: qPCR test for SARS-CoV-2, anonymized electronic health
215 records, primary care and death registry data. We report results based on the 12 September 2020
216 data refresh and excluded from the analysis 28,547 individuals with a death registry event prior to
217 2020.
218
219 **COVID-19 phenotypes used for genetic association analyses**
220 We grouped participants from each study into three broad COVID-19 disease categories
221 (**Supplementary Table 2**): (i) positive – those with a positive qPCR or serology test for SARS-
222 CoV-2, or a COVID-19-related ICD10 code (U07), hospitalization or death; (ii) negative – those
223 with only negative qPCR or serology test results for SARS-CoV-2 and no COVID-19-related
224 ICD10 code (U07), hospitalization or death; and (iii) unknown – those with no qPCR or serology
225 test results and no COVID-19-related ICD10 code (U07), hospitalization or death. We then used
226 these broad COVID-19 disease categories, in addition to hospitalization and disease severity
227 information, to create seven COVID-19-related phenotypes for genetic association analyses, as
228 detailed in **Supplementary Table 3**.
229
230 **Array genotyping**
231 Genotyping was performed on one of four SNP array types: Illumina OmniExpress Exome array
232 (OMNI; 59345 samples from GHS), Illumina Global Screening Array (GSA; PMBB and 82,527
233 samples from GHS), Applied Biosystems UK BiLEVE Axiom Array (49,950 samples from UKB),
234 or Applied Biosystems UK Biobank Axiom Array (438,427 samples from UKB). We retained
235 variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-Weinberg

236 equilibrium test *P*-value>10^{-15}. Array data were then used: (i) to define ancestry subsets; and (ii)
237 to generate a polygenic risk score (PRS) predictor, as part of the exome-wide association analyses
238 carried out in REGENIE (see below).
239
240 **Exome sequencing**
241 *Sample Preparation and Sequencing.* Genomic DNA samples normalized to approximately 16
242 ng/ul were transferred to the Regeneron Genetics Center from the UK Biobank in 0.5ml 2D matrix
243 tubes (Thermo Fisher Scientific) and stored in an automated sample biobank (LiCONiC
244 Instruments) at -80°C prior to sample preparation. Exome capture was completed using a high-
245 throughput, fully-automated approach developed at the Regeneron Genetics Center. Briefly, DNA
246 libraries were created by enzymatically shearing 100ng of genomic DNA to a mean fragment size
247 of 200 base pairs using a custom NEBNext Ultra II FS DNA library prep kit (New England
248 Biolabs) and a common Y-shaped adapter (Integrated DNA Technologies [IDT]) was ligated to
249 all DNA libraries. Unique, asymmetric 10 base pair barcodes were added to the DNA fragment
250 during library amplification with KAPA HiFi polymerase (KAPA Biosystems) to facilitate
251 multiplexed exome capture and sequencing. Equal amounts of sample were pooled prior to
252 overnight exome capture, approximately 16 hours, with either (i) a slightly modified version of
253 IDT's xGen probe library (for UKB, PMBB and 81,620 samples of GHS); or (ii) NimbleGen
254 VCRome (58,856 samples of GHS). Captured fragments were bound to streptavidin-coupled
255 Dynabeads (Thermo Fisher Scientific) and non-specific DNA fragments removed through a series
256 of stringent washes using the xGen Hybridization and Wash kit according to the manufacturer's
257 recommended protocol (Integrated DNA Technologies). The captured DNA was PCR amplified
258 with KAPA HiFi and quantified by qPCR with a KAPA Library Quantification Kit (KAPA

259 Biosystems). The multiplexed samples were pooled and then sequenced using: (i) for UKB
260 samples – 75 bp paired-end reads with two 10 base pair index reads on the Illumina NovaSeq 6000
261 platform using S2 or S4 flow cells; (ii) for GHS samples captured with VCRome – 75 bp paired-
262 end reads with two 8 bp index reads on the Illumina HiSeq 2500; (iii) for GHS captured with IDT
263 – two 8 bp index reads on the Illumina HiSeq 2500 or two 10 bp index reads on the Illumina
264 NovaSeq 6000 on S4 flow cells; (iv) for UPENN-PMBB – two 10 bp index reads on the Illumina
265 NovaSeq 6000 on S4 flow cells.
266
267 *Variant calling and quality control*. Sample read mapping and variant calling, aggregation and
268 quality control were performed via the SPB protocol described in Van Hout et al. [29]. Briefly, for
269 each sample, NovaSeq WES reads are mapped with BWA MEM to the hg38 reference genome.
270 Small variants are identified with WeCall and reported as per-sample gVCFs. These gVCFs are
271 aggregated with GLnexus into a joint-genotyped, multi-sample VCF (pVCF). SNV genotypes with
272 read depth (DP) less than seven and indel genotypes with read depth less than ten are changed to
273 no-call genotypes. After the application of the DP genotype filter, a variant-level allele balance
274 filter is applied, retaining only variants that meet either of the following criteria: (i) at least one
275 homozygous variant carrier or (ii) at least one heterozygous variant carrier with an allele balance
276 (AB) greater than the cutoff (AB ≥ 0.15 for SNVs and AB ≥ 0.20 for indels).
277
278 *Identification of low-quality variants from exome-sequencing using machine learning.* Briefly, in
279 each study, we defined a set of positive control and negative control variants based on: (i)
280 concordance in genotype calls between array and exome sequencing data; (ii) Mendelian
281 inconsistencies in the exome sequencing data; (iii) differences in allele frequencies between exome

282 sequencing batches (UKB and GHS); (iv) variant loadings on 20 principal components derived
283 from the analysis of variants with a MAF<1%; (v) transmitted singletons. The model was then
284 trained on up to 30 available WeCall/GLnexus site quality metrics, including, for example, allele
285 balance and depth of coverage. We split the data into training (80%) and test (20%) sets. We
286 performed a grid search with 5-fold cross-validation on the training set to identify the
287 hyperparameters that return the highest accuracy during cross-validation, which are then applied
288 to the test set to confirm accuracy. This approach identified as low-quality a total of 7 million
289 variants in the UKB study (86% in the buffer region), 7.2 million across the two GHS datasets
290 (IDT and VCRome; 84% in the buffer region) and 1.1 million in the PMBB study (88% in the
291 buffer region). These variants were removed from analysis in the respective studies.
292
293 *Gene burden masks.* Briefly, for each gene region as defined by Ensembl [30], genotype
294 information from multiple rare coding variants was collapsed into a single burden genotype, such
295 that individuals who were: (i) homozygous reference (Ref) for all variants in that gene were
296 considered homozygous (RefRef); (ii) heterozygous for at least one variant in that gene were
297 considered heterozygous (RefAlt); (iii) and only individuals that carried two copies of the
298 alternative allele (Alt) of the same variant were considered homozygous for the alternative allele
299 (AltAlt). We did not phase rare variants; compound heterozygotes, if present, were considered
300 heterozygous (RefAlt). We did this separately for four classes of variants: (i) predicted loss of
301 function (pLoF), which we refer to as an "M1" burden mask; (ii) pLoF or missense ("M2"); (iii)
302 pLoF or missense variants predicted to be deleterious by 5/5 prediction algorithms ("M3"); (iv)
303 pLoF or missense variants predicted to be deleterious by 1/5 prediction algorithms ("M4").
304 Variants were annotated using SnpEff 4.3[31] and the most severe consequence for each variant

305 was chosen, considering complete protein-coding transcripts for each gene. The following variants
306 were considered to be pLoF variants: frameshift-causing indels, variants affecting splice acceptor
307 and donor sites, variants leading to stop gain, stop loss and start loss. The five missense deleterious
308 algorithms used were SIFT [32], PolyPhen2 (HDIV), PolyPhen2 (HVAR) [33], LRT [34], and
309 MutationTaster [35]. For each gene, and for each of these four groups, we considered five separate
310 burden masks, based on the frequency of the alternative allele of the variants that were screened
311 in that group: <1%, <0.1%, <0.01%, <0.001% and singletons only. Each burden mask was then
312 tested for association with the same approach used for individual variants (see below).
313

314 **Genetic association analyses**

315 Association analyses in each study were performed using the genome-wide Firth logistic
316 regression test implemented in REGENIE [14]. In this implementation, Firth's approach is applied
317 when the p-value from standard logistic regression score test is below 0.05. As the Firth penalty
318 (*i.e.* Jeffrey's invariant prior) corresponds to a data augmentation procedure where each
319 observation is split into a case and a control with different weights, it can handle variants with no
320 minor alleles among cases. With no covariates, this corresponds to adding 0.5 in every cell of a
321 2x2 table of allele counts versus case-control status.

322 We included in step 1 of REGENIE (*i.e.* prediction of individual trait values based on the
323 genetic data) array variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-
324 Weinberg equilibrium test P-value>10^{-15} and linkage-disequilibrium (LD) pruning (1000 variant
325 windows, 100 variant sliding windows and r^2<0.9). The exception was the GHS study, for which
326 we used exome (not array) variants in step 1; we did this because two different exome capture
327 technologies (IDT and VCRome) were used to sequence the GHS samples, and so it was important

328 to capture in step 1 of REGENIE any differences in exome sequencing performance between IDT
329 and VCRome. We excluded from step 1 any SNPs with high inter-chromosomal LD, in the major
330 histo-compatibility (MHC) region, or in regions of low complexity.

331 The association model used in step 2 of REGENIE included as covariates (i) age, age^2, sex,
332 age-by-sex and age^2-by-sex; (ii) 10 ancestry-informative principle components (PCs) derived from
333 the analysis of a set of LD-pruned (50 variant windows, 5 variant sliding windows and r^2<0.5)
334 common variants from the array (imputed for the GHS study) data; (iii) an indicator for exome
335 sequencing batch (GHS: two IDT batches, one VCRome batch; UKB: six IDT batches); and (iv)
336 20 PCs derived from the analysis of exome variants with a MAF between 2.6×10^{-5} (roughly
337 corresponding to a minor allele count [MAC] of 20) and 1%. We corrected for PCs built from rare
338 variants because previous studies demonstrated PCs derived from common variants do not
339 adequately correct for fine-scale population structure [36, 37].

340 Within each study, association analyses were performed separately for five different
341 continental ancestries defined based on the array data: African (AFR), Admixed American (AMR),
342 European (EUR) and South Asian (SAS). We determined continental ancestries by projecting each
343 sample onto reference principle components calculated from the HapMap3 reference panel.
344 Briefly, we merged our samples with HapMap3 samples and kept only SNPs in common between
345 the two datasets. We further excluded SNPs with MAF<10%, genotype missingness >5% or
346 Hardy-Weinberg Equilibrium test p-value < 10^{-5}. We calculated PCs for the HapMap3 samples
347 and projected each of our samples onto those PCs. To assign a continental ancestry group to each
348 non-HapMap3 sample, we trained a kernel density estimator (KDE) using the HapMap3 PCs and
349 used the KDEs to calculate the likelihood of a given sample belonging to each of the five
350 continental ancestry groups. When the likelihood for a given ancestry group was >0.3, the sample

351 was assigned to that ancestry group. When two ancestry groups had a likelihood >0.3, we
352 arbitrarily assigned AFR over EUR, AMR over EUR, AMR over EAS, SAS over EUR, and AMR
353 over AFR. Samples were excluded from analysis if no ancestry likelihoods were >0.3, or if more
354 than three ancestry likelihoods were > 0.3.

355 Results were subsequently meta-analyzed across studies and ancestries using an inverse
356 variance-weighed fixed-effects meta-analysis.

357

358 **Gene expression analysis in participants of the GHS study**

359 For a subset of individuals from the GHS study (n=1,988, ascertained through the Geisinger
360 Bariatric Surgery Clinic), RNA was extracted from liver biopsies conducted during bariatric
361 surgery to evaluate liver disease. Individuals had class 3 obesity (BMI>40kg/m^2) or class 2 obesity
362 (BMI 35-39 kg/m^2) with an obesity-related co-morbidity (e.g. type-2 diabetes, hypertension, sleep
363 apnea, non-alcoholic fatty liver disease). RNA libraries were prepared using polyA-extraction and
364 then sequenced with 75bp paired-end reads with two 10 bp index reads on the Illumina NovaSeq
365 6000 on S4 flow cells. RNA-seq data were then analyzed using the GTEx v8 workflow[38], using
366 STAR [39] and RNASeqQC [40], except that GENCODE v32 was used in lieu of v26. Briefly: (i)
367 raw expression counts were normalized with TMM (Trimmed Mean of M-values) as implemented
368 in edgeR [40]; (ii) a rank-based inverse normal transformation was applied to the normalized
369 expression values; (iii) principal components (PCs) analysis was performed on data from 25,078
370 genes with TPM >0.1 in >20% samples, to identify latent factors accounting for variation in gene
371 expression; (iv) gene expression levels were adjusted for the top 100 PCs to improve power to
372 identify cis-regulatory effects.

373

374 **Frequency of *EEF2* rare promoter variant in COVID-19 cases from independent studies**

375 To help understand if the association between COVID-19 risk and rs532051930 in *EEF2* was
376 likely to be a true-positive association, we determine its frequency in 4,341 cases from three
377 additional studies.

378 *GenOMICC (n=2,969).* Individuals with severe COVID-19 were ascertained as described
379 previously[11]. DNA samples were then whole-genome sequenced on the Illumina NovaSeq 6000
380 platform, aligned to the human reference genome hg38 and variant called to GVCF stage on the
381 DRAGEN pipeline (software v01.011.269.3.2.22, hardware v01.011.269) at Genomics England.
382 rs532051930 +/-50bp was genotyped with the GATK GenotypeGVCFs tool v4.1.8.1 and filtered
383 to minimum depth 8X. Ancestry for individuals with array genotyping was inferred using
384 ADMIXTURE[41] populations defined in 1000 Genomes[42]. When one individual had a
385 probability > 80% of pertaining to one ancestry, then the individual was assigned to this ancestry,
386 otherwise the individual was considered to be of admixed ancestry, as performed in the Million
387 veteran program [43]. Somalier v0.2.12[44] was used to estimate ancestry for samples with whole-
388 genome sequencing data. Predictions from Somalier were compared against predictions from
389 ADMIXTURE for 1833 samples with both array genotyping and whole-genome sequencing data.
390 Of these, the ancestry assignment matched between the two approaches for 1832 samples.
391 Somalier predictions were used for the remaining 927 samples, of which 813 could be confidently
392 (≥95% probability) assigned to a population; the remaining 114 were assigned to admixed
393 ancestry.

394 *Columbia University COVID-19 biobank (n=1,152).* This cohort has previously been
395 described in detail[22]. Briefly, 1,152 COVID-19 patients that were treated for COVID-19 at the
396 Columbia University Irving Medical Center were recruited to the Columbia University COVID-

397 19 Biobank between March and May 2020. All patients had PCR-confirmed SARS-CoV-2
398 infection and the vast majority had severe COVID-19 requiring hospitalization. For all cases,
399 exomes were captured with the IDT xGen Exome Research Panel V1.0 and sequenced on
400 Illumina's NovaSeq 6000 platform with 150 bp paired-end reads according to standard protocols.
401 All cases were processed with the same bioinformatic pipeline for variant calling. In brief, reads
402 were aligned to human reference GRCh37 using DRAGEN and duplicates were marked with
403 Picard. Variants were called according to the Genome Analysis Toolkit (GATK) Best Practices
404 recommendations v3.66[45]. Finally, variants were annotated with ClinEff[31] and the IGM's in-
405 house tool ATAV[46]. A centralized database was used to store variant and per site coverage data
406 for all samples enabling well controlled analyses without the need of generating jointly called VCF
407 files (see Ren et al. 2020 for details[46]). For each patient, we performed ancestry classification
408 into one of the six major ancestry groups (European, African, Latinx, East Asian, South Asian and
409 Middle Eastern) using a neural network trained on a set of samples with known ancestry labels.
410 We used a 50% probability cut-off to assign an ancestry label to each sample and labeled samples
411 that did not reach 50% for any of the ancestral groups as "Admixed".

412 We only included samples that had at least 90% of the consensus coding sequence (CCDS
413 release 20[47]) covered at ≥ 10x and ≤ 3% contamination levels according to VerifyBamID[48].
414 Additionally, we removed samples with a discordance between self-declared and sequence-derived
415 gender and samples with an inferred relationship of second-degree or closer according to
416 KING[49]. All cases had at least 10x coverage at the position of rs532051930.

417 *Biobanque Québec Covid-19 (n=220).* The Biobanque Québec COVID-19
418 (www.BQC19.ca) is a provincial biobank prospectively enrolling patients with suspected COVID-
419 19, or COVID-19 confirmed through SARS-CoV-2 PCR testing and was previously described[22].

420 For this study, we used results from patients with available WGS data and who were recruited at
421 the Jewish General Hospital (JGH) in Montreal. The JGH is a university affiliated hospital serving
422 a large multi-ethnic adult population and the Québec government designated the JGH as the primary
423 COVID-19 reference center early in the pandemic. In total, Biobanque Quebec contained 533
424 participants with WGS, including 62 cases of COVID-19 who required invasive ventilatory support
425 (BiPAP, high flow oxygen, or endotracheal intubation) or died, 128 COVID-19 patients who were
426 hospitalized but did not require invasive ventilatory support, 30 individuals with COVID-19 did not
427 require hospitalization, and 313 SARS-CoV-2 PCR-negative participants. Using genetic PCAs
428 derived from genome-wide genotyping, 76% of participants were of European ancestry, 9% were
429 of African ancestry, 7% were of east Asian ancestry, and 5% were of south Asian ancestry.
430 We performed WGS at a mean depth of 30x on all individuals using Illumina's Novaseq
431 6000 platform (Illumina, San Diego, CA, USA). Sequencing results were analyzed using the
432 McGill Genome Center bioinformatics pipelines[50], in accordance with Genome Analysis
433 Toolkit (GATK) best practices recommendations[45]. Reads were aligned to the GRCh38
434 reference genome. Variant quality control was performed using the variantRecalibrator and
435 applyVQSR functions from GATK.
436
437 **Results availability**
438 All genotype-phenotype association results reported in this study are available for browsing using
439 the RGC's COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use
440 is limited to research purposes in accordance with the Terms of Use (https://rgc-
441 covid19.regeneron.com/terms-of-use). The COVID-19 Results Browser provides a user-friendly
442 interface to explore genetic association results, enabling users to query summary statistics across

443 multiple cohorts and association studies using genes, variants or phenotypes of interest. Results
444 are displayed in an interactive tabular view ordered by p-value – enabling filtering, sorting,
445 grouping and viewing additional statistics – with link outs to individual GWAS reports, including
446 interactive Manhattan and QQ plots. LocusZoom views of LD information surrounding variants
447 of interest are also available, with LD calculated using the respective source genetic datasets.

448 The data resource supporting the COVID-19 Results Browser was built using a processed
449 version of the raw association analysis outputs. Using the RGC's data engineering toolkit based in
450 Apache Spark and Project Glow (https://projectglow.io/), association results were annotated,
451 enriched and partitioned into a distributed, columnar data store using Apache Parquet. Processed
452 Parquet files were registered with AWS Athena, which enables efficient, scalable queries on
453 unfiltered association result datasets. Additionally, "filtered" views of associations significant at a
454 threshold of p-value < 0.001 were stored in AWS RDS Aurora databases for low latency queries
455 to service primary views of top associations. APIs into RDS and Athena are managed behind the
456 scenes such that results with a p-value>0.001 are pulled from Athena as needed.

457

458 **Competing interests**

459 J.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., D.S., F.S.P.K., J.D.B., C.O'D.,
460 A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, H.M.K., L.D., E.S., M.J., S.B., K.S.M, W.J.S.,
461 A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees
462 and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. X.Z., S.E.,
463 J.W.D. are employees of AbbVie and may hold stock in AbbVie. Financial support for this
464 research was provided by AbbVie through the UKB Exome Sequencing Consortium. AbbVie
465 participated in the interpretation of data, review, and approval of the publication. P.N. and M.M.P

466 are employees and stockholders of Alnylam Pharmaceuticals. J.B.R. has served as an advisor to
467 GlaxoSmithKline and Deerfield Capital and these agencies had no role in the design,
468 implementation or interpretation of this study. S.S., E.W., A.C.P., and E.N.S. are employed by
469 Takeda. S.S. holds shares in Takeda and Janssen. The other authors declare no competing interests.
470

471 **Acknowledgements**

472 This research has been conducted using the UK Biobank Resource (Project 26041). The Penn
473 Medicine BioBank is funded by a gift from the Smilow family, the National Center for
474 Advancing Translational Sciences of the National Institutes of Health under CTSA Award
475 Number UL1TR001878, and the Perelman School of Medicine at the University of
476 Pennsylvania. Whole genome sequencing of the Biobanque Québec Covid-19 cohort was funded
477 by the CanCOGeN HostSeq project. The Richards research group is supported by the Canadian
478 Institutes of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital,
479 the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK and the
480 Fonds de Recherche Québec Santé (FRQS). G.B.L. is supported by a joint research fellowship
481 from Quebec's ministry of health and social services, and the FRQS. T.N. is supported by
482 Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists
483 and JSPS Overseas Challenge Program for Young Researchers. J.B.R. is supported by a FRQS
484 Clinical Research Scholarship. The Columbia University Biobank was supported by Columbia
485 University and the National Center for Advancing Translational Sciences, NIH, through Grant
486 Number UL1TR001873. Columbia University COVID-19 Biobank members that additionally
487 contributed to this work include Muredach P. Reilly, Wendy Chung, Eldad Hod, Soumitra
488 Sengupta, Danielle Pendrick, Nitin Bhardwaj, Ning Shang, Atlas Khan, Chen Wang, Sheila M.

489 O'Byrne, Renu Nandakumar, Amritha Menon, Yat S. So, Richard Mayeux, Ali G. Gharavi,
490 Iuliana Ionita-Laza, Andrea Califano, Christine K. Garcia, Peter Sims, and Anne-Catrin
491 Uhlemann. The content is solely the responsibility of the authors and does not necessarily
492 represent the official views of the NIH or Columbia University. GenOMICC was funded by
493 Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome-Beit
494 Prize award to J. K. Baillie (Wellcome Trust 103258/Z/13/A), a BBSRC Institute Program
495 Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and
496 BBS/E/D/30002275), the Medical Research Council [grant MC_PC_19059]. Research
497 performed at the Human Genetics Unit was funded by the MRC (MC_UU_00007/10,
498 MC_UU_00007/15). Whole-genome sequencing was done in partnership with Genomics
499 England and was funded by UK Department of Health and Social Care, UKRI and LifeArc.
500 Genomics England and the 100,000 Genomes Project was funded by the National Institute for
501 Health Research, the Wellcome Trust, the Medical Research Council, Cancer Research UK, the
502 Department of Health and Social Care and NHS England. M Caulfield is an NIHR Senior
503 Investigator. This work is part of the portfolio of translational research at the NIHR Biomedical
504 Research Centre at Barts and Cambridge. LK was supported by an RCUK Innovation Fellowship
505 from the National Productivity Investment Fund (MR/R026408/1). We acknowledge support
506 from the MRC Human Genetics Unit programme grant, "Quantitative traits in health and
507 disease" (U. MC_UU_00007/10). A. Tenesa acknowledges funding from MRC research grant
508 MR/P015514/1, and HDR-UK award HDR-9004 and HDR-9003. Recruitment to GenOMICC
509 was enabled by the National Institute of Healthcare Research Clinical Research Network (NIHR
510 CRN) and the Chief Scientist Office (Scotland), who facilitate recruitment into research studies
511 in NHS hospitals, and to the global ISARIC and InFACT consortia. We thank the patients and

512 their loved ones who volunteered to contribute to this study at one of the most difficult times in
513 their lives, and the research staff in every intensive care unit who recruited patients at personal
514 risk during the most extreme conditions we have ever witnessed in UK hospitals.

515 **Supplementary Figures**



516

517

518 **Supplementary Figure 1. Association between a rare promoter variant in EEF2**
519 **(rs532051930:A) and the COVID-19 hospitalization phenotype. (A)** Regional association plot
520 centered on rs532051930. Orange triangles: individual rare variants (MAF<0.5%). Green squares:
521 burden tests. Grey circles: individual common variants (MAF>0.5%). **(B)** Forest plot showing
522 association in the two individual datasets included in the meta-analysis of this variant. **(C)** Results
523 from a population-scale PROcap (Precision Run-On 5' cap sequencing) study [19], which profiles
524 transcription start sites of nascent RNAs attached to RNA polymerase. The variant rs532051930
525 (vertical red line) is located 2 bp away from the peak of transcription initiation. (**D**) Distribution
526 of *EEF2* expression among 1,918 individuals from the GHS study with available RNA-seq data
527 from liver tissue. Vertical red line indicates expression levels for the only individual who was
528 heterozygote for the rare promoter variant rs532051930.

529 **TABLES**

530

531 **Table 1. Top rare variant associations identified in this study ($P<10^{-8}$), all observed with the**

532 **phenotype COVID-19 positive and hospitalized (cases) vs. COVID-19 negative or unknown**

533 **(controls).**

Variant	Effect allele	Odds Ratio [95% CI]	P-value	N cases with 0|1|2 copies of effect allele	N controls with 0|1|2 copies of effect allele	Effect allele frequency	Gene	Variant effect
rs374698271	T	81.60 [18.71,355.81]	4.65E-09	1698|5|0	399222|18|0	0.00003	*RFX2*	Intronic
rs532051930	A	93.90 [20.29,434.50]	6.17E-09	1869|4|0	508510|22|0	0.00003	*EEF2*	5 prime UTR
rs751932982	A	22.68 [7.89,65.23]	6.92E-09	1869|2|2	508247|44|8	0.00006	*FAM9B*	Intronic

534

535 **Table 2.** Association between the phenotype COVID-19 positive and hospitalized (cases) vs
536 COVID-19 negative or unknown (controls) and 14 genes related to interferon signaling that were
537 recently reported to contain rare (MAF<0.1%), deleterious variants in patients with severe
538 COVID-19 [14, 23].

Variants included in burden test	Gene	Odds Ratio (95% CI)	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF
pLoF, MAF<0.1%	*IFNAR1*	0.805[0.146;4.438]	8.00E-01	2019|1|0	525406|359|0	0.00034
	IFNAR2	2.077[0.620;6.961]	2.40E-01	2082|3|0	534277|688|0	0.00064
	IKBKG	0.491[0.005;50.219]	7.60E-01	1873|0|0	508491|31|10	0.00005
	IRF3	0.956[0.251;3.643]	9.50E-01	2083|2|0	534559|406|0	0.00038
	IRF7	1.165[0.426;3.185]	7.70E-01	2082|3|0	534124|841|0	0.00079
	IRF9	0.371[0.003;53.766]	7.00E-01	1873|0|0	508479|53|0	0.00005
	STAT1	0.365[0.001;126.712]	7.40E-01	1873|0|0	508490|42|0	0.00004
	STAT2	0.355[0.028;4.438]	4.20E-01	1873|0|0	508405|127|0	0.00012
	TBK1	0.365[0.011;11.964]	5.70E-01	1873|0|0	508445|87|0	0.00009
	TICAM1	3.730[0.189;73.610]	3.90E-01	1872|1|0	508368|164|0	0.00016
	TLR3	1.128[0.144;8.834]	9.10E-01	2084|1|0	534674|291|0	0.00027
	TLR7	7.627[1.872;31.075]	4.60E-03	1872|0|1	508503|25|4	0.00003
	TRAF3	0.368[0.000;733.638]	8.00E-01	1873|0|0	508504|28|0	0.00003
	UNC93B1	1.302[0.272;6.238]	7.40E-01	1938|2|0	516861|409|0	0.0004
pLoF or missense predicted deleterious, MAF<0.1%	*IFNAR1*	0.756[0.234;2.444]	6.40E-01	2083|2|0	534219|746|0	0.0007
	IFNAR2	1.968[0.598;6.469]	2.70E-01	2082|3|0	534253|712|0	0.00067
	IKBKG	0.446[0.010;19.737]	6.80E-01	1873|0|0	508452|70|10	0.00009
	IRF3	0.786[0.238;2.592]	6.90E-01	2083|2|0	534413|552|0	0.00052
	IRF7	1.137[0.519;2.492]	7.50E-01	2080|5|0	533486|1479|0	0.00138
	IRF9	0.371[0.003;53.766]	7.00E-01	1873|0|0	508479|53|0	0.00005
	STAT1	0.365[0.038;3.488]	3.80E-01	2018|0|0	526009|218|0	0.00021
	STAT2	2.600[1.272;5.314]	8.80E-03	2073|12|0	533405|1559|1	0.00146
	TBK1	1.114[0.445;2.790]	8.20E-01	2081|4|0	533861|1103|1	0.00103
	TICAM1	3.657[0.188;71.218]	3.90E-01	1872|1|0	508365|167|0	0.00016
	TLR3	0.805[0.435;1.493]	4.90E-01	2077|8|0	532355|2609|1	0.00244
	TLR7	1.580[0.627;3.979]	3.30E-01	2001|3|1	525830|477|163	0.00076
	TRAF3	3.013[0.527;17.217]	2.10E-01	2019|1|0	525523|242|0	0.00023
	UNC93B1	1.665[0.774;3.582]	1.90E-01	2075|10|0	533331|1634|0	0.00153

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.

539

540 **SUPPLEMENTARY TABLES**
541

542 **Supplementary Tables 1 to 10 are provided in a separate document.**

543

544 **Supplementary Table 1.** Demographics and clinical characteristics of study participants.

545

546 **Supplementary Table 2.** Breakdown of COVID-19 status across the four studies included in the

547 analysis.

548

549 **Supplementary Table 3.** Definitions used for the seven COVID-19 phenotypes analyzed.

550

551 **Supplementary Table 4.** Genomic inflation factor (λ_{GC}) observed in the analysis of exome

552 sequence variants for each of the eight phenotypes tested.

553

554 **Supplementary Table 5.** Association between the COVID-19 hospitalization phenotype and 50

555 rare variants in the promoter of *EEF2*.

556

557 **Supplementary Table 6.** Evidence for association between the COVID-19 hospitalization

558 phenotype and rs532051930 across different association tests.

559

560 **Supplementary Table 7.** No carriers of the rare variant rs532051930 in the promoter of EEF2

561 were observed in an additional 4,122 individuals with COVID-19.

562

563 **Supplementary Table 8.** Results from burden association tests for 167 genes located in eight loci
564 described in Horowitz et al. [13].
565
566 **Supplementary Table 9.** Results from burden association tests for 14 genes related to interferon
567 signaling and recently reported to contain rare (MAF<0.1%), deleterious variants in patients with
568 severe COVID-19.
569
570 **Supplementary Table 10.** Results from burden association tests for an additional 32 genes that
571 are involved in the etiology of SARS-CoV-2, encode therapeutic targets or have been implicated
572 in other immune or infectious diseases through GWAS.

573 **References**

574 1. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019.* New
575 England Journal of Medicine, 2020. **382**(8): p. 727-733.
576 2. Coronaviridae Study Group of the International Committee on Taxonomy of, V., *The*
577 *species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV*
578 *and naming it SARS-CoV-2.* Nat Microbiol, 2020. **5**(4): p. 536-544.
579 3. Guan, W.J., et al., *Clinical Characteristics of Coronavirus Disease 2019 in China.* N Engl J
580 Med, 2020. **382**(18): p. 1708-1720.
581 4. Kimball, A., et al., *Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents*
582 *of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.*
583 MMWR Morb Mortal Wkly Rep, 2020. **69**(13): p. 377-381.
584 5. Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19.* JAMA, 2020.
585 **323**(14): p. 1406-1407.
586 6. Richardson, S., et al., *Presenting Characteristics, Comorbidities, and Outcomes Among*
587 *5700 Patients Hospitalized With COVID-19 in the New York City Area.* Jama, 2020.
588 **323**(20): p. 2052-2059.
589 7. Atkins, J.L., et al., *PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER*
590 *ADULTS IN THE UK BIOBANK COMMUNITY COHORT.* medRxiv, 2020: p.
591 2020.05.06.20092700.
592 8. Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with*
593 *COVID-19 in Wuhan, China: a retrospective cohort study.* Lancet, 2020. **395**(10229): p.
594 1054-1062.
595 9. Cummings, M.J., et al., *Epidemiology, clinical course, and outcomes of critically ill adults*
596 *with COVID-19 in New York City: a prospective cohort study.* Lancet, 2020. **395**(10239):
597 p. 1763-1770.
598 10. Shelton, J.F., et al., *Trans-ethnic analysis reveals genetic and non-genetic associations*
599 *with COVID-19 susceptibility and severity.* medRxiv, 2020: p. 2020.09.04.20188318.
600 11. Pairo-Castineira, E., et al., *Genetic mechanisms of critical illness in Covid-19.* Nature,
601 2020.
602 12. Ellinghaus, D., et al., *Genomewide Association Study of Severe Covid-19 with Respiratory*
603 *Failure.* New England Journal of Medicine, 2020.
604 13. Horowitz, J.E., Kosmicki, J. A., et al. , *Common genetic variants identify therapeutic*
605 *targets for COVID-19 and individuals at high risk of severe disease.* medRxiv, 2020.
606 **2020.12.14.20248176**.
607 14. Mbatchou, J., et al., *Computationally efficient whole genome regression for quantitative*
608 *and binary traits.* bioRxiv, 2020: p. 2020.06.19.162354.
609 15. Valiente-Echeverria, F., et al., *eEF2 and Ras-GAP SH3 domain-binding protein (G3BP1)*
610 *modulate stress granule assembly during HIV-1 infection.* Nat Commun, 2014. **5**: p. 4819.
611 16. Fernandez, I.S., et al., *Initiation of translation by cricket paralysis virus IRES requires its*
612 *translocation in the ribosome.* Cell, 2014. **157**(4): p. 823-31.
613 17. Zhou, J. and O.G. Troyanskaya, *Predicting effects of noncoding variants with deep*
614 *learning-based sequence model.* Nat Methods, 2015. **12**(10): p. 931-4.

615 18. Ferraro, N.M., et al., *Transcriptomic signatures across human tissues identify functional*
616 *rare genetic variation.* Science, 2020. **369**(6509).
617 19. Kristjansdottir, K., et al., *Population-scale study of eRNA transcription reveals bipartite*
618 *functional enhancer architecture.* Nat Commun, 2020. **11**(1): p. 5963.
619 20. Ma, C., et al., *Recommended joint and meta-analysis strategies for case-control*
620 *association testing of single low-count variants.* Genet Epidemiol, 2013. **37**(6): p. 539-50.
621 21. Sofer, T., *BinomiRare: A robust test of the association of a rare variant with a disease for*
622 *pooled analysis and meta-analysis, with application to the HCHS/SOL.* Genet Epidemiol,
623 2017. **41**(5): p. 388-395.
624 22. Povysil, G., et al., *Failure to replicate the association of rare loss-of-function variants in*
625 *type I IFN immunity genes with severe COVID-19.* medRxiv, 2020: p.
626 2020.12.18.20248226.
627 23. Consortium, G.T., *The GTEx Consortium atlas of genetic regulatory effects across human*
628 *tissues.* Science, 2020. **369**(6509): p. 1318-1330.
629 24. Cheloufi, S., et al., *The histone chaperone CAF-1 safeguards somatic cell identity.* Nature,
630 2015. **528**(7581): p. 218-24.
631 25. van der Made, C.I., et al., *Presence of Genetic Variants Among Young Men With Severe*
632 *COVID-19.* JAMA, 2020.
633 26. Zhang, S.Y., et al., *Severe COVID-19 in the young and healthy: monogenic inborn errors of*
634 *immunity?* Nat Rev Immunol, 2020. **20**(8): p. 455-456.
635 27. Dewey, F.E., et al., *Distribution and clinical impact of functional variants in 50,726*
636 *whole-exome sequences from the DiscovEHR study.* Science, 2016. **354**(6319).
637 28. Park, J., et al., *A genome-first approach to aggregating rare genetic variants in LMNA for*
638 *association with electronic health record phenotypes.* Genet Med, 2020. **22**(1): p. 102-
639 111.
640 29. Van Hout, C.V., et al., *Exome sequencing and characterization of 49,960 individuals in*
641 *the UK Biobank.* Nature, 2020.
642 30. Zerbino, D.R., et al., *Ensembl 2018.* Nucleic Acids Research, 2017. **46**(D1): p. D754-D761.
643 31. Cingolani, P., et al., *A program for annotating and predicting the effects of single*
644 *nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster*
645 *strain w1118; iso-2; iso-3.* Fly (Austin), 2012. **6**(2): p. 80-92.
646 32. Vaser, R., et al., *SIFT missense predictions for genomes.* Nat Protoc, 2016. **11**(1): p. 1-9.
647 33. Adzhubei, I., D.M. Jordan, and S.R. Sunyaev, *Predicting functional effect of human*
648 *missense mutations using PolyPhen-2.* Curr Protoc Hum Genet, 2013. **7**(1): p. 7.20.1-
649 7.20.41.
650 34. Chun, S. and J.C. Fay, *Identification of deleterious mutations within three human*
651 *genomes.* Genome research, 2009. **19**(9): p. 1553-1561.
652 35. Schwarz, J.M., et al., *MutationTaster evaluates disease-causing potential of sequence*
653 *alterations.* Nat Methods, 2010. **7**(8): p. 575-6.
654 36. Mathieson, I. and G. McVean, *Differential confounding of rare and common variants in*
655 *spatially structured populations.* Nature Genetics, 2012. **44**(3): p. 243-246.
656 37. Zaidi, A.A. and I. Mathieson, *Demographic history impacts stratification in polygenic*
657 *scores.* bioRxiv, 2020: p. 2020.07.20.212530.

658 38. Consortium, G.T., *The Genotype-Tissue Expression (GTEx) project.* Nat Genet, 2013.
659 **45**(6): p. 580-5.
660 39. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics, 2013. **29**(1):
661 p. 15-21.
662 40. Robinson, M.D. and A. Oshlack, *A scaling normalization method for differential*
663 *expression analysis of RNA-seq data.* Genome Biol, 2010. **11**(3): p. R25.
664 41. Alexander, D.H. and K. Lange, *Enhancements to the ADMIXTURE algorithm for individual*
665 *ancestry estimation.* BMC Bioinformatics, 2011. **12**: p. 246.
666 42. Auton, A., et al., *A global reference for human genetic variation.* Nature, 2015.
667 **526**(7571): p. 68-74.
668 43. Gaziano, J.M., et al., *Million Veteran Program: A mega-biobank to study genetic*
669 *influences on health and disease.* J Clin Epidemiol, 2016. **70**: p. 214-23.
670 44. Pedersen, B.S., et al., *Somalier: rapid relatedness estimation for cancer and germline*
671 *studies using efficient genome sketches.* Genome Med, 2020. **12**(1): p. 62.
672 45. Van der Auwera, G.A., et al., *From FastQ data to high confidence variant calls: the*
673 *Genome Analysis Toolkit best practices pipeline.* Curr Protoc Bioinformatics, 2013.
674 **43**(1110): p. 11.10.1-11.10.33.
675 46. Ren, Z., G. Povysil, and D.B. Goldstein, *ATAV: a comprehensive platform for population-*
676 *scale genomic analyses.* bioRxiv, 2020(p. 2020.06.08.136507.).
677 47. Pruitt, K.D., et al., *The consensus coding sequence (CCDS) project: Identifying a common*
678 *protein-coding gene set for the human and mouse genomes.* Genome Res, 2009. **19**(7):
679 p. 1316-23.
680 48. Jun, G., et al., *Detecting and estimating contamination of human DNA samples in*
681 *sequencing and array-based genotype data.* Am J Hum Genet, 2012. **91**(5): p. 839-48.
682 49. Manichaikul, A., et al., *Robust relationship inference in genome-wide association studies.*
683 Bioinformatics, 2010. **26**(22): p. 2867-73.
684 50. Bourgey, M., et al., *GenPipes: an open-source framework for distributed and scalable*
685 *genomic analyses.* Gigascience, 2019. **8**(6).
686

687 **SUPPLEMENTARY TEXT**

688

689 **Regeneron Genetics Center (RGC) Research Team and Contribution Statements**

690 All authors/contributors are listed in alphabetical order.

691

692 **RGC Management and Leadership Team**

693 Goncalo Abecasis, Ph.D., Aris Baras, M.D., Michael Cantor, M.D., Giovanni Coppola, M.D.,
694 Aris Economides, Ph.D., Luca A. Lotta, M.D., Ph.D., John D. Overton, Ph.D., Jeffrey G. Reid,
695 Ph.D., Alan Shuldiner, M.D.

696 Contribution: All authors contributed to securing funding, study design and oversight. All
697 authors reviewed the final version of the manuscript.

698

699 **Sequencing and Lab Operations**

700 Christina Beechert, Caitlin Forsythe, M.S., Erin D. Fuller, Zhenhua Gu, M.S., Michael Lattari,
701 Alexander Lopez, M.S., John D. Overton, Ph.D., Thomas D. Schleicher, M.S., Maria
702 Sotiropoulos Padilla, M.S., Louis Widom, Sarah E. Wolf, M.S., Manasi Pradhan, M.S., Kia
703 Manoochehri, Ricardo H. Ulloa.

704 Contribution: C.B., C.F., A.L., and J.D.O. performed and are responsible for sample genotyping.
705 C.B, C.F., E.D.F., M.L., M.S.P., L.W., S.E.W., A.L., and J.D.O. performed and are responsible
706 for exome sequencing. T.D.S., Z.G., A.L., and J.D.O. conceived and are responsible for
707 laboratory automation. M.P., K.M., R.U., and J.D.O are responsible for sample tracking and the
708 library information management system.

709

710 **Clinical Informatics**

711 Nilanjana Banerjee, Ph.D., Michael Cantor, M.D. M.A., Dadong Li, Ph.D., Deepika Sharma,
712 MHI

713 Contribution: All authors contributed to the development and validation of clinical phenotypes
714 used to identify study subjects and (when applicable) controls.

715

716 **Genome Informatics**

717 Xiaodong Bai, Ph.D., Suganthi Balasubramanian, Ph.D., Andrew Blumenfeld, Gisu Eom, Lukas
718 Habegger, Ph.D., Alicia Hawes, B.S., Shareef Khalid, Jeffrey G. Reid, Ph.D., Evan K. Maxwell,
719 Ph.D., William Salerno, Ph.D., Jeffrey C. Staples, Ph.D.

720 Contribution: X.B., A.H., W.S. and J.G.R. performed and are responsible for analysis needed to
721 produce exome and genotype data. G.E. and J.G.R. provided compute infrastructure
722 development and operational support. S.B., and J.G.R. provide variant and gene annotations and
723 their functional interpretation of variants. E.M., J.S., A.B., L.H., J.G.R. conceived and are
724 responsible for creating, developing, and deploying analysis platforms and computational
725 methods for analyzing genomic data.

726

727 **Analytical Genetics**

728 Gonçalo R. Abecasis, Ph.D., Joshua Backman, Ph.D., Manuel A. Ferreira, Ph.D., Lauren Gurski,
729 Jack A. Kosmicki, Ph.D., Alexander H. Li, Ph.D., Adam E. Locke, Ph.D., Anthony Marcketta,
730 Jonathan Marchini, Ph.D., Joelle Mbatchou, Ph.D., Shane McCarthy, Ph.D., Colm O'Dushlaine,
731 Ph.D., Dylan Sun, Kyoko Watanabe, Ph.D.

732 Contribution: J.A.K. and M.A.F. performed association analyses and led manuscript writing
733 group. J.B. identified low-quality variants in exome sequence data using machine learning. L.G.
734 and K.W. helped with visualization of association results. A.H.L., A.E.L., A.M. and D.S.
735 prepared the analytical pipelines to perform association analyses. J.M. and J.M. developed and
736 helped deploy REGENIE. S.M. and C.O'D. helped defined COVID-19 phenotypes. G.R.A.
737 supervised all analyses. All authors contributed to and reviewed the final version of the
738 manuscript.
739
740 **Immune, Respiratory, and Infectious Disease Therapeutic Area Genetics**
741 Julie E. Horowitz, PhD.
742 Contribution: J.E.H. helped defined COVID-19 phenotypes, interpret association results and led
743 the manuscript writing group.
744
745 **Research Program Management**
746 Marcus B. Jones, Ph.D., Michelle LeBlanc, Ph.D., Jason Mighty, Ph.D., Lyndon J. Mitnaul,
747 Ph.D.
748 Contribution: All authors contributed to the management and coordination of all research
749 activities, planning and execution. All authors contributed to the review process for the final
750 version of the manuscript.
751

752 **UK Biobank Exome Sequencing Consortium Research Team**

753

754 **[1]Bristol Myers Squibb**

755 Oleg Moiseyenko, Carlos Rios, Saurabh Saha

756

757 **[2]Regeneron Pharmaceuticals Inc.**

758 Listed in pages 38 to 40.

759

760 **[3]Biogen Inc.**

761 Sally John, Chia-Yen Chen, David Sexton, Paola G. Bronson, Christopher D. Whelan, Varant

762 Kupelian, Eric Marshall, Timothy Swan, Susan Eaton, Jimmy Z. Liu, Stephanie Loomis, Megan

763 Jensen, Saranya Duraisamy, Ellen A. Tsai, Heiko Runz

764

765 **[4]Alnylam Pharmaceuticals**

766 Aimee M. Deaton, Margaret M. Parker, Lucas D. Ward, Alexander O. Flynn-Carroll, Greg

767 Hinkle, Paul Nioi

768

769 **[5]AstraZeneca**

770 Olympe Chazara, Sri VV. Deevi, Xiao Jiang, Amanda O'Neill, Slavé Petrovski, Katherine

771 Smith, Quanli Wang

772

773 **[6]Takeda California Inc**

774 Jason Tetrault, Dorothee Diogo, Aldo Cordova Palomera, Emily Wong, Rajesh Mikkilineni,
775 David Merberg, Sunita Badola, Erin N. Smith, Sandor Szalma
776
777 **[7]Pfizer, Inc**
778 Yi-Pin Lai, Xing Chen, Xinli Hu, Melissa R. Miller
779
780 **[8]Abbvie**
781 Xiuwen Zheng, Bridget Riley-Gillis, Jason Grundstad, Sahar Esmaeeli, Jeff Waring, J. Wade
782 Davis
783
784 [1]Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08543, USA
785 [2]Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591,
786 USA
787 [3]Biogen Inc., 225 Binney Street, Cambridge, MA 02139, USA
788 [4]Alnylam Pharmaceuticals, 675 West Kendall St, Cambridge, MA 02142, USA
789 [5]AstraZeneca Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D,
790 Cambridge, UK
791 [6]Takeda California Inc., 9625 Towne Centre Dr, San Diego, CA 92121, USA
792 [7] Pfizer, Inc., 1 Portland Street, Cambridge MA 02139, USA
793 [8] AbbVie, Inc., 1 N. Waukegan Rd, North Chicago, IL 60064, USA
794
795

796 **GenOMICC Consortium**

797 Sara Clohisey[1], Fiona Griffiths[1], James Furniss[1], James Furniss[1], Trevor Paterson[1], Tony
798 Wackett[1], Ruth Armstrong[1], Wilna Oosthuyzen[1], Nick Parkinson[1], Max Head Fourman[1], Andrew
799 Law[1], Veronique Vitart[2], Lucija Klaric[2], Anne Richmond[2], Chris P. Ponting[2], Andrew D.
800 Bretherick[2], Charles Hinds[3], Timothy Walsh[4], Sean Keating[4], Clark D Russell[1,5], Malcolm G.
801 Semple[6,7], Kathy Rowan[8], Elvina Gountouna[9], Nicola Wrobel[10], Lee Murphy[10], Angie Fawkes[10],
802 Richard Clark[10], Audrey Coutts[10], Lorna Donnelly[10], Tammy Gilchrist[10], Katarzyna Hafezi[10],
803 Louise Macgillivray[10], Alan Maclean[10], Sarah McCafferty[10], Kirstie Morrice[10], , Angie Fawkes[10],
804 Julian Knight[11], Charlotte Summers[12], Manu Shankar-Hari[13,14], Peter Horby[15], Alistair
805 Nichol[16,17,18], David Maslove[19], Lowell Ling[20], Danny McAuley[21,22], Hugh Montgomery[23], Peter
806 J.M. Openshaw[24,25].

807 [1]Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK

808 [2]MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of

809 Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

810 [3]William Harvey Research Institute, Barts and the London School of Medicine and Dentistry,

811 Queen Mary University of London, London EC1M 6BQ, UK

812 [4]Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16

813 5SA, UK

814 [5]Centre for Inflammation Research, The Queen's Medical Research Institute, University of

815 Edinburgh, 47 Little France Crescent, Edinburgh, UK

816 [6]NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of

817 Infection, Veterinary and Ecological Sciences University of Liverpool, Liverpool, L69 7BE, UK

818 [7]Respiratory Medicine, Alder Hey Children's Hospital, Institute in The Park, University of

819 Liverpool, Alder Hey Children's Hospital, Liverpool, UK

820 [8]Intensive Care National Audit & Research Centre, London, UK

821 [9]Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine,

822 University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

823 [10]Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh,

824 EH4 2XU, UK

825 [11]Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

826 [12]Department of Medicine, University of Cambridge, Cambridge, UK

827 [13]Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust,

828 London, UK

829 [14]School of Immunology and Microbial Sciences, King's College London, UK

830 [15]Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University

831 of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK

832 [16]Clinical Research Centre at St Vincent's University Hospital, University College Dublin,

833 Dublin, Ireland

834 [17]Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne,

835 Australia

836 [18]Intensive Care Unit, Alfred Hospital, Melbourne, Australia

837 [19]Department of Critical Care Medicine, Queen's University and Kingston Health Sciences

838 Centre, Kingston, ON, Canada

839 [20]Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince

840 of Wales Hospital, Hong Kong, China

841 [21]Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast,

842 Northern Ireland, UK

843 [22]Department of Intensive Care Medicine, Royal Victoria Hospital, Belfast, Northern Ireland,

844 UK

845 [23]UCL Centre for Human Health and Performance, London, W1T 7HA, UK

846 [24]National Heart and Lung Institute, Imperial College London, London, UK

847 [25]Imperial College Healthcare NHS Trust: London, London, UK

848

SUPPLEMENTARY FIGURES

A.



B.



C.



D.



<u>Supplementary Figure 1.</u> Association between a rare promoter variant in *EEF2* (rs532051930:A) and the COVID-19 hospitalization phenotype. (A) Regional association plot centered on rs532051930. Orange triangles: individual rare variants (MAF<0.5%). Green squares: burden tests. Grey circles: individual common variants (MAF>0.5%). **(B)** Forest plot showing association in the two individual datasets included in the meta-analysis of this variant. **(C)** Results from a population-scale PROcap (Precision Run-On 5' cap sequencing) study [19], which profiles transcription start sites of nascent RNAs attached to RNA polymerase. The variant rs532051930 (vertical red line) is located 2 bp away from the peak of transcription initiation. **(D)** Distribution of *EEF2* expression among 1,918 individuals from the GHS study with available RNA-seq data from liver tissue. Vertical red line indicates expression levels for the only individual who was heterozygote for the rare promoter variant rs532051930.

SUPPLEMENTARY TABLES

Supplementary Table 1. Demographics and clinical characteristics of study participants.

Demographics	COVID-19 Positive		Covid-19 Negative or Unknown
	Hospitalized	Not Hospitalized	
UK Biobank			
Total N	1848	5400	416935
AFR ancestry, n (%)	80 (3.8)	134 (2.2)	8495 (1.8)
EUR ancestry, n (%)	1703 (81.9)	5030 (83.2)	399240 (85.7)
SAS ancestry, n (%)	65 (3.1)	236 (3.9)	9200 (1.9)
Average Age, y (% >60y)	59.7 (57)	52.6 (22)	56.2 (36)
Female, n (%)	737 (39.8)	2896 (53.6)	229572 (55.1)
Hypertension, n (%)	884 (47.8)	1214 (22.5)	96851 (23.2)
Cardiovascular Disease, n (%)	265 (14.3)	330 (6.1)	24859 (5.8)
Type 2 Diabetes, n (%)	342 (18.5)	378 (7)	25335 (6.1)
Chronic kidney disease, n (%)	134 (7.3)	112 (2.1)	8096 (1.9)
Asthma, n (%)	343 (18.5	886 (16.4)	59229 (14.2)
COPD, n (%)	208 (11.2)	164 (3)	10117 (2.4)
GHS			
Total N	170	664	109292
EUR ancestry, n (%)	170 (100)	664 (100)	109292 (100)
Average Age, y (% >60y)	67.81 (76.47)	54.74 (39.0)	55.75 (44.14)
Female, n (%)	90 (52.94)	435 (65.51)	68226 (62.42)
Hypertension, n (%)	138 (81.17)	343 (51.65)	53658 (49.09)
Cardiovascular Disease, n (%)	77 (45.29)	108 (16.26)	17269 (15.80)
Type 2 Diabetes, n (%)	73 (42.94)	158 (23.79)	23290 (21.30)
Chronic kidney disease, n (%)	64 (37.64)	94 (14.15)	14246 (13.03)
Asthma, n (%)	15 (8.82)	47 (7.07)	6975 (6.38)
COPD, n (%)	47(27.64)	67 (10.09)	10822 (9.90)
PMBB			
Total N	67	99	959
AFR ancestry, n (%)	67 (100)	99 (100)	959 (100)
Average Age, y (% >60y)	62.58 (61.19)	47.64 (19.19)	56.24 (43.27)
Female, n (%)	38 (56.7)	72 (72.7)	641 (66.8)
Hypertension, n (%)	59 (88.1)	52 (52.5)	704 (73.4)
Cardiovascular Disease, n (%)	40 (59.7)	17 (17.2)	359 (37.4)
Type 2 Diabetes, n (%)	50 (74.6)	31 (31.3)	440 (45.9)
Chronic kidney disease, n (%)	42 (62.7)	13 (13.1)	300 (31.3)
Asthma, n (%)	18 (26.9)	23 (23.2)	294 (30.7)
COPD, n (%)	20 (29.9)	8 (8.1)	145 (15.1)

Supplementary Table 2. Breakdown of COVID-19 status across the four studies included in the analysis.

COVID-19 status	Positive qPCR or serology for SARS-CoV-2	ICD10 U07 diagnosis or hospitalization	Severe COVID-19 (ventilation or death)	Negative qPCR or serology test for SARS-CoV-2				
					UK Biobank	GHS	PMBB	Total
Positive	Yes	Yes	Yes	Yes or No or NA	382	49	27	458
	Yes	Yes	No or NA	Yes or No or NA	1119	121	40	1,280
	Yes	No or NA	Yes	Yes or No or NA	0	0	0	0
	Yes	No or NA	No or NA	Yes or No or NA	5400	664	99	6,163
	No or NA	Yes	Yes	No or NA	122	0	0	122
	No or NA	Yes	No or NA	No or NA	77	0	0	77
	No or NA	No or NA	Yes	No or NA	0	0	0	0
	No or NA	Yes	Yes	Yes	37	0	0	37
	No or NA	Yes	No or NA	Yes	111	0	0	111
	No or NA	No or NA	Yes	Yes	0	0	0	0
					Total = 7248	Total = 834	Total = 166	Total = 8248
Negative	No or NA	No or NA	No or NA	Yes	32,867	15,574	959	49,400
Unknown	NA	No or NA	No or NA	NA	384,068	93,718	7,779	485,565
Total					424,183	110,126	8,904	543,213

Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed.

Broad phenotype category	Phenotype	Case/control group	Definition			Sample size with genetic data			
			COVID-19 status	Hospitalized	Severe disease	UK Biobank	GHS	PMBB	Total
Risk of infection	COVID-19 positive vs. COVID-19 negative or unknown	Cases	Positive	Yes, No or NA	Yes, No or NA	7,248	834	166	8,248
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	8,738	534,965
	COVID-19 positive vs. COVID-19 negative	Cases	Positive	Yes, No or NA	Yes, No or NA	7,248	834	166	8,248
		Controls	Negative	No or NA	No or NA	32,867	15,574	959	49,400
	COVID-19 positive and not hospitalized vs. COVID-19 negative or unknown	Cases	Positive	No	No	5,400	664	99	6,163
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	8,738	534,965
	COVID-19 positive and hospitalized vs. COVID-19 negative or unknown	Cases	Positive	Yes (or death)	Yes, No or NA	1,848	170	67	2,085
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	8,738	534,965
	COVID-19 positive and severe vs. COVID-19 negative or unknown	Cases	Positive	Yes, No or NA	Yes	541	49	NA	590
		Controls	Negative or unknown	No or NA	No or NA	416,935	109,292	NA	526,227
Risk of adverse outcomes amongst infected individuals	COVID-19 positive and hospitalized vs. COVID-19 positive and not hospitalized	Cases	Positive	Yes (or death)	Yes, No or NA	1,703	170	67	1,940
		Controls	Positive	No	No	5,030	664	99	5,793
	COVID-19 positive and severe vs. COVID-19 positive and not hospitalized	Cases	Positive	Yes, No or NA	Yes	523	49	NA	572
		Controls	Positive	No	No	5,164	664	NA	5,828

Supplementary Table 4. Genomic inflation factor (lambda GC) observed in the analysis of exome sequence variants for each of the seven phenotypes tested.

Phenotype	Study	Ancestry	N cases	N controls	Exome-sequencing variants with MAF<0.5% & MAC>=5			Exome-sequencing variants with MAF<0.5% & MAC>25			Exome-sequencing variants with MAF>0.5%		
					N variants	Proportion of variants with MAC=0 in cases	Lambda GC	N variants	Proportion of variants with MAC=0 in cases	Lambda GC	N variants	Proportion of variants with MAC=0 in cases	Lambda GC
COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown_combined	UKB_Freeze_450	SAS	65	9200	798145	0.873	0.202	222553	0.719	0.774	227664	0.193	1.254
	UPENN-PMBB_Freeze_One	AFR	67	8738	890983	0.857	0.215	279379	0.708	0.748	486699	0.132	1.099
	UKB_Freeze_450	AFR	80	8495	812651	0.830	0.268	248412	0.653	0.803	380222	0.120	0.947
	GHS_Freeze_145_Exome	EUR	170	109292	2899753	0.933	0.042	889226	0.815	0.23	172227	0.046	0.997
	UKB_Freeze_450	EUR	1703	399240	6411484	0.849	0.126	2074846	0.622	0.555	166323	0.000	1.004
	Meta-analysis	ALL	2085	534965	8053662	0.832	0.126	2833904	0.599	0.554	352116	0.043	1.02
COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	UPENN-PMBB_Freeze_One	AFR	67	99	NA	NA	NA	NA	NA	NA	330315	0.012	0.183
	GHS_Freeze_145_Exome	EUR	170	664	209299	0.549	0.866	NA	NA	NA	173449	0.035	1.079
	UKB_Freeze_450	EUR	1703	5030	424564	0.072	1.099	112045	0.000	1.043	166403	0.000	1.037
	Meta-analysis	ALL	1940	5793	462977	0.126	1.017	128932	0.000	1.021	398264	0.009	0.388
COVID19_positive_not_hospitalized_vs_COVID19_negative_or_unknown_combined	UPENN-PMBB_Freeze_One	AFR	99	8738	893407	0.796	0.338	280294	0.596	0.992	487296	0.076	0.961
	UKB_Freeze_450	AFR	134	8495	816964	0.736	0.48	250786	0.492	1.218	379423	0.050	0.998
	UKB_Freeze_450	SAS	236	9200	808557	0.652	0.622	226850	0.325	1.326	227147	0.016	1.016
	GHS_Freeze_145_Exome	EUR	664	109292	2907752	0.824	0.167	892254	0.559	0.731	172221	0.001	1.016
	UKB_Freeze_450	EUR	5030	399240	6440585	0.722	0.345	2086994	0.387	1.074	166350	0.000	1.019
	Meta-analysis	ALL	6163	534965	8091286	0.710	0.345	2849393	0.385	1.059	351738	0.020	0.982
COVID19_positive_severe_vs_COVID19_negative_or_unknown_combined	UKB_Freeze_450	SAS	18	9200	796240	0.961	0.04	222161	0.910	0.163	226990	0.496	0.749
	UKB_Freeze_450	AFR	33	8495	811241	0.919	0.132	248076	0.831	0.346	379346	0.302	0.821
	GHS_Freeze_145_Exome	EUR	49	109292	2895469	0.976	0.013	888545	0.932	0.08	172229	0.246	0.785
	UKB_Freeze_450	EUR	490	399240	6400400	0.931	0.034	2070233	0.812	0.176	166321	0.001	1.02
	Meta-analysis	ALL	590	526227	7876462	0.917	0.037	2721522	0.783	0.214	225588	0.090	0.889
COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	UKB_Freeze_450	AFR	33	134	NA	NA	NA	NA	NA	NA	235941	0.109	0.234
	GHS_Freeze_145_Exome	EUR	49	664	194798	0.818	0.273	NA	NA	NA	170209	0.228	1.141
	UKB_Freeze_450	EUR	490	5030	373269	0.327	1.078	87177	0.043	1.013	166184	0.001	0.998
	Meta-analysis	ALL	572	5828	410271	0.365	0.912	101899	0.035	0.968	301689	0.056	0.593
COVID19_positive_vs_COVID19_negative_combined	UPENN-PMBB_Freeze_One	AFR	166	959	195274	0.331	1.345	NA	NA	NA	484596	0.023	0.974
	UKB_Freeze_450	AFR	214	766	141313	0.206	1.071	NA	NA	NA	387132	0.013	0.938
	UKB_Freeze_450	SAS	301	844	149617	0.129	1.111	NA	NA	NA	228543	0.004	1.07
	GHS_Freeze_145_Exome	EUR	834	15574	896282	0.505	0.889	239671	0.091	1.024	172248	0.000	1.019
	UKB_Freeze_450	EUR	6733	31257	1361423	0.143	1.15	417941	0.001	1.015	166646	0.000	1
	Meta-analysis	ALL	8248	49400	1745716	0.203	1.023	575968	0.005	1.025	471978	0.006	0.984
COVID19_positive_vs_COVID19_negative_or_unknown_combined	UPENN-PMBB_Freeze_One	AFR	166	8738	897805	0.700	0.519	282679	0.434	1.219	486918	0.029	0.972
	UKB_Freeze_450	AFR	214	8495	821371	0.636	0.666	253263	0.335	1.356	379070	0.015	1.02
	UKB_Freeze_450	SAS	301	9200	812263	0.595	0.735	228572	0.246	1.267	226861	0.007	1.012
	GHS_Freeze_145_Exome	EUR	834	109292	2910461	0.799	0.205	893247	0.509	0.844	172192	0.001	1.026
	UKB_Freeze_450	EUR	6733	399240	6455895	0.675	0.446	2093385	0.315	1.175	166339	0.000	1.017
	Meta-analysis	ALL	8248	534965	8111082	0.663	0.443	2857926	0.315	1.161	351576	0.009	0.996

Supplementary Table 5. Association between the COVID-19 hospitalization phenotype and 50 rare variants in the promoter of EEF2.

rs ID	hg38	Effect allele	Odds Ratio	95% LCI	95% UCI	SE	P-value	Effect allele frequencty	N cases with 0|1|2 copies of effect allele	N controls with 0|1|2 copies of effect allele	Studies analyzed
rs532051930	19:3985461:G:A	A	93.9065	20.2954	434.505	0.7816	6.18E-09	2.55E-05	1869|4|0	508510|22|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs374797871	19:3985414:A:G	G	24.2157	1.84809	317.299	1.3127	0.0152	0.000547	146|1|0	17215|18|0	UKB_Freeze_450_AFR UPENN-PMBB_Freeze_One_AFR Meta
rs754033543	19:3985383:T:C	C	18.9215	1.73245	206.658	1.2198	0.0159	0.000027	1702|1|0	399219|21|0	UKB_Freeze_450_EUR Meta
rs542049090	19:3985437:A:G	G	18.6529	1.72231	202.014	1.2155	0.0161	0.000026	1769|1|0	407947|20|0	UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs897131413	19:3985457:G:C	C	17.7894	1.63807	193.191	1.2169	0.0180	0.000047	1872|1|0	508477|47|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs370100022	19:3985421:G:A	A	5.21063	1.10233	24.6302	0.7925	0.0373	0.000140	1936|2|0	517585|144|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR UKB_Freeze_450_SAS Meta
rs546488032	19:3985433:G:A	A	6.19102	0.776398	49.3674	1.0593	0.0852	0.000057	1937|1|0	517671|56|1	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR UKB_Freeze_450_SAS_ Meta
rs201347619	19:3985401:T:A	A	0.364401	0.0678296	1.95767	0.8578	0.2393	0.004028	147|0|0	17094|138|1	UKB_Freeze_450_AFR UPENN-PMBB_Freeze_One_AFR Meta
rs369523513	19:3985436:G:A	A	0.36233	0.0593301	2.21276	0.9232	0.2715	0.000116	2020|0|0	525596|120|1	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_AFR UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs373888946	19:3985451:G:T	T	0.363709	0.0429819	3.07768	1.0896	0.3533	0.000204	1873|0|0	508319|208|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs907273439	19:3985443:G:C	C	2.35632	0.354027	15.6831	0.9671	0.3755	0.000234	1871|2|0	508270|237|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs190787427	19:3985426:G:C	C	0.361534	0.0260517	5.0172	1.342	0.4484	0.000117	1938|0|0	517565|122|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR UKB_Freeze_450_SAS Meta
rs377104055	19:3985429:T:C	C	0.361136	0.0234969	5.55049	1.3941	0.4650	0.000087	1850|0|0	416400|73|0	UKB_Freeze_450_AFR UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs200921166	19:3985402:C:T	T	0.360523	0.00840259	15.4686	1.9179	0.5948	0.000064	1703|0|0	399187|51|0	UKB_Freeze_450_EUR Meta
rs774095261	19:3985425:C:A	A	0.352361	0.00521284	23.8177	2.1498	0.6275	0.000020	1850|0|0	416437|17|0	UKB_Freeze_450_AFR UKB_Freeze_450_EUR UPENN-PMBB_Freeze_One_AFR Meta
rs529755390	19:3985441:T:C	C	0.361172	0.00447913	29.123	2.2398	0.6493	0.000049	1873|0|0	508368|50|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs777439048	19:3985423:A:C	C	0.377494	0.00480048	29.6849	2.227	0.6618	0.000062	1873|0|0	508457|63|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs1196793724	19:3985434:C:G	G	0.364183	0.00328972	40.3162	2.4015	0.6740	0.000044	1703|0|0	399202|35|0	UKB_Freeze_450_EUR Meta
rs529755390	19:3985441:T:A	A	0.364438	0.0027381	48.5061	2.4955	0.6859	0.000047	1703|0|0	399119|38|0	UKB_Freeze_450_EUR Meta
NA	985441:T:TGGCGGCGACCGGCGAC		0.364656	0.00182461	72.878	2.7029	0.7090	0.000044	1873|0|0	508368|45|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs190787427	19:3985426:G:A	A	0.365569	0.00170724	78.2788	2.7381	0.7132	0.000042	1703|0|0	399120|34|0	UKB_Freeze_450_EUR Meta
rs1280637004	19:3985463:G:A	A	0.364255	0.000412394	321.736	3.4611	0.7704	0.000024	1703|0|0	399215|19|0	UKB_Freeze_450_EUR Meta
rs563082396	19:3985435:C:A	A	0.364183	0.000353722	374.953	3.5393	0.7753	0.000034	1873|0|0	508468|35|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
NA	19:3985425:C:G	G	0.36411	0.000282174	469.838	3.6545	0.7822	0.000021	1703|0|0	399217|17|0	UKB_Freeze_450_EUR Meta
rs374912847	19:3985392:G:A	A	0.362584	0.000204629	642.464	3.8163	0.7904	0.000014	1703|0|0	399229|11|0	UKB_Freeze_450_EUR Meta
NA	19:3985455:G:A	A	0.363455	0.000175147	754.22	3.8969	0.7951	0.000016	1703|0|0	399227|13|0	UKB_Freeze_450_EUR Meta
rs750678552	19:3985430:C:G	G	0.35912	0.000113616	1135.11	4.1116	0.8033	0.000432	65|0|0	9192|8|0	UKB_Freeze_450_SAS Meta
rs776567094	19:3985428:G:A	A	0.365423	6.02E-05	2218.87	4.4447	0.8208	0.000019	1703|0|0	399218|15|0	UKB_Freeze_450_EUR Meta
rs369523513	19:3985436:G:C	C	0.366851	5.09E-05	2645.82	4.5325	0.8249	0.000018	1873|0|0	508462|18|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR_ Meta
NA	19:3985417:G:C	C	0.363855	2.93E-05	4517.18	4.8096	0.8335	0.000014	1703|0|0	399224|11|0	UKB_Freeze_450_EUR Meta
rs1027642860	19:3985460:A:C	C	0.36092	1.49E-05	8736.83	5.1503	0.8431	0.000009	1703|0|0	399229|7|0	UKB_Freeze_450_EUR Meta
rs779559837	19:3985438:G:A	A	0.391097	3.10E-05	4928.25	4.8172	0.8455	0.000110	170|0|0	109251|24|0	GHS_Freeze_145_MegaFreeze_EUR Meta
NA	19:3985444:C:T	T	0.382166	1.81E-05	8071.45	5.0807	0.8498	0.000022	1873|0|0	508485|22|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs776029459	19:3985405:C:G	G	0.374486	1.16E-05	12130.2	5.2989	0.8530	0.000017	1873|0|0	508513|17|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
NA	19:3985411:A:G	G	0.364948	5.36E-06	24871	5.6784	0.8591	0.000006	1703|0|0	399231|5|0	UKB_Freeze_450_EUR Meta
rs995814367	19:3985458:G:A	A	0.365204	3.21E-06	41519	5.9395	0.8653	0.000012	1703|0|0	399229|10|0	UKB_Freeze_450_EUR Meta
rs764194249	19:3985408:G:A	A	0.365204	2.04E-06	65358.2	6.171	0.8703	0.000006	1703|0|0	399234|5|0	UKB_Freeze_450_EUR Meta
NA	19:3985442:G:A	A	0.366228	1.12E-06	119957	6.4794	0.8768	0.000009	1703|0|0	399223|7|0	UKB_Freeze_450_EUR Meta
rs777439048	19:3985423:A:G	G	0.366667	6.02E-07	223245	6.7957	0.8826	0.000015	1703|0|0	399223|12|0	UKB_Freeze_450_EUR Meta
rs886610889	19:3985452:A:ACGG	ACGG	0.383391	9.78E-07	150305	6.5711	0.8840	0.000046	170|0|0	109273|10|0	GHS_Freeze_145_MegaFreeze_EUR Meta
rs748898673	19:3985399:A:C	C	0.366228	4.01E-07	334091	7.002	0.8859	0.000009	1703|0|0	399233|7|0	UKB_Freeze_450_EUR Meta
rs560636284	19:3985439:G:A	A	0.92441	0.310456	2.75251	0.5567	0.8877	0.000897	1870|3|0	507593|913|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta
rs776567094	19:3985428:G:C	C	0.365825	2.96E-07	451572	7.1563	0.8882	0.000009	1703|0|0	399218|7|0	UKB_Freeze_450_EUR Meta
rs1019385884	19:3985467:G:A	A	0.366008	2.35E-07	569136	7.2741	0.8901	0.000007	1703|0|0	399229|6|0	UKB_Freeze_450_EUR Meta
rs1037024876	19:3985452:A:G	G	0.34294	5.19E-08	2.26E+06	8.0119	0.8937	0.000023	170|0|0	109273|5|0	GHS_Freeze_145_MegaFreeze_EUR Meta
rs754780163	19:3985431:G:A	A	0.366888	1.38E-07	973791	7.5469	0.8943	0.000012	1703|0|0	399227|10|0	UKB_Freeze_450_EUR Meta
NA	19:3985432:C:G	G	0.367034	7.63E-10	1.77E+08	10.2002	0.9217	0.000006	1703|0|0	399235|5|0	UKB_Freeze_450_EUR Meta
NA	19:3985449:A:G	G	0.375987	7.77E-10	1.82E+08	10.2028	0.9236	0.000027	170|0|0	109282|6|0	GHS_Freeze_145_MegaFreeze_EUR Meta
NA	19:3985446:G:A	A	0.367402	2.56E-13	5.28E+11	14.2826	0.9441	0.000006	1703|0|0	399232|5|0	UKB_Freeze_450_EUR Meta
rs373344045	19:3985424:G:A	A	1.06354	0.140046	8.07673	1.0344	0.9525	0.000243	1872|1|0	508283|247|0	GHS_Freeze_145_MegaFreeze_EUR UKB_Freeze_450_EUR Meta

Supplementary Table 6. Evidence for association between the COVID-19 hospitalization phenotype and rs532051930 across different association tests.

Approach	Association test in individual studies	Approach used to combine results across studies	Association in UKB Europeans			Association in GHS Europeans			Association in UKB+GHS Europeans		
			OR (95% CI)	SE*	P-value	OR (95% CI)	SE*	P-value	OR (95% CI)	SE*	P-value
1 (default)	REGENIE Firth exact test, with covariates and LOCO	Inverse-variance fixed-effects meta-analysis	80.9 (13.1 - 499.5)	0.93	2.20E-06	134.8 (7.9 - 2301.3)	1.45	7.07E-04	93.9 (20.3 - 434.5)	0.78	6.17E-09
2		Sample size weighted meta-analysis							NA		3.14E-08
3		Meta-analysis of log-likelihood curves							85.6 (17.2 - 425.8)	0.82	5.51E-08
4	Firth exact test, no covariates	Inverse-variance fixed-effects meta-analysis	65.7 (16.9 - 195.3)	0.90	3.49E-06	92.1 (9.9 - 395.0)	1.4	0.00127	72.5 (16.4 - 321.0)	0.76	1.64E-08
5	Fisher's exact test (no covariates)		58.7 (10.6 - 218.5)	0.98	3.35E-05	64.6 (1.48 - 456.8)	1.75	0.017	60.1 (11.2 - 321.6)	0.86	1.70E-06
6	Logistic regression, with covariates		71.6 (15.6 - 241.7)	0.99	1.55E-05	106.5 (5.61 - 648.2)	1.74	0.00733	78.9 (14.6 - 425.0)	0.86	3.73E-07
7	Logistic regression, no covariates		58.7 (13.4 - 185.0)	0.96	2.37E-05	64.7 (3.51 - 340.4)	1.67	0.0123	60.2 (11.7 - 308.4)	0.83	9.00E-07
8	BinomiRare test, with covariates	Meta-analysis	NA		1.19E-05	NA		5.53E-05	NA		2.96E-07
9	Firth exact test, with covariates	Mega-analysis (UKB+GHS combined)	NA			NA			85.8 (17.2 - 427.2)	0.82	5.48E-08
10	Firth exact test, no covariates								54.4 (11.8 - 250.5)	0.78	2.91E-07
11	Fisher's exact test (no covariates)								49.4 (9.7 - 251.0)	0.83	2.53E-06
12	Logistic regression, with covariates								78.7 (14.6- 424.9)	0.86	3.88E-07
13	Logistic regression, no covariates								49.5 (9.9 - 246.2)	0.82	1.89E-06

*Re-calculated from the OR and p-value

Supplementary Table 7. No carriers of the rare variant rs532051930 in the promoter of EEF2 were observed in an additional 4,341 individuals with COVID-19.

Study	Reference	N COVID-19 cases				
		Total	Hospitalized	Severe	Of European|African|Asian|Hispanic|other ancestry	Heterozygote for rs532051930:A
GenOMICC	PMID 33307546	2969	2969	2969	2110 | 145 | 375 | NA | 339	0
Columbia University COVID-19 Biobank	https://www.medrxiv.org/content/10.1101/2020.12.18.20248226v2	1152	1082	479	67 | 463 | 33 | 506 | 83	0
Biobanque Québec Covid-19	https://www.medrxiv.org/content/10.1101/2020.12.18.20248226v2	220	128	62	154 | 30 | 29 | 7 | 0	0

Supplementary Table 8. Results from burden association tests for 167 genes located in eight loci described by Horowitz et al. (2021).

Trait	Gene	Burden test	MAF	Odds Ratio [95% CI]	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF	GWAS SNP	Distance to GWAS SNP, bp	Distance to GWAS SNP, rank
COVID19 positive hospitalized vs COVID19 negative or unknown	*CHAF1A*	M1	<1%	25.216[4.947;128.539]	1.00E-04	1935|3|0	517687|45|0	0.00005	19:4719431:G:A	316669	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*CHAF1A*	M3	<1%	25.216[4.947;128.539]	1.00E-04	1935|3|0	517687|45|0	0.00005	19:4719431:G:A	316669	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*SLC22A31*	M1	<1%	5.583[1.807;17.256]	2.80E-03	1844|6|0	416071|402|0	0.00049	16:89117727	78271	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*SLC22A31*	M3	<1%	5.583[1.807;17.256]	2.80E-03	1844|6|0	416071|402|0	0.00049	16:89117727	78271	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*SARDH*	M1	<1%	2.367[1.315;4.259]	4.00E-03	2072|12|1	533477|1487|1	0.0014	9:133270015:A:C	393873	25
COVID19 positive hospitalized vs COVID19 negative or unknown	*SHD*	M1	<1%	5.283[1.619;17.242]	5.80E-03	1869|4|0	508290|242|0	0.00024	19:4719431:G:A	439368	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*CTB-50L17.10*	M1	<1%	5.726[1.598;20.518]	7.40E-03	2017|3|0	525625|140|0	0.00014	19:4719431:G:A	247081	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*CTB-50L17.10*	M3	<1%	5.726[1.598;20.518]	7.40E-03	2017|3|0	525625|140|0	0.00014	19:4719431:G:A	247081	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*DBH*	M1	<1%	0.320[0.128;0.796]	1.40E-02	2083|2|0	532761|2204|0	0.00205	9:133270015:A:C	366356	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC14*	M1	<1%	6.544[1.434;29.868]	1.50E-02	1936|2|0	517625|95|12	0.00012	19:51739497	96143	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*OLIG2*	M1	<1%	12.046[1.255;115.574]	3.10E-02	1872|1|0	508456|76|0	0.00008	21:33252612:A:G	225750	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*OLIG2*	M3	<1%	12.046[1.255;115.574]	3.10E-02	1872|1|0	508456|76|0	0.00008	21:33252612:A:G	225750	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*PSORS1C2*	M1	<1%	5.176[1.151;23.275]	3.20E-02	1871|2|0	508350|182|0	0.00018	6:31153649:G:A	15699	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*PPP2R1A*	M3	<1%	5.429[1.129;26.105]	3.50E-02	1871|2|0	508337|195|0	0.00019	19:51739497	450599	33
COVID19 positive hospitalized vs COVID19 negative or unknown	*SH3GL1*	M1	<1%	10.804[1.173;99.499]	3.60E-02	1872|1|0	508459|73|0	0.00007	19:4719431:G:A	357832	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*MICB*	M1	<1%	2.106[1.007;4.401]	4.80E-02	2077|8|0	533921|1043|1	0.00098	6:31153649:G:A	344544	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*MICB*	M3	<1%	2.106[1.007;4.401]	4.80E-02	2077|8|0	533921|1043|1	0.00098	6:31153649:G:A	344544	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*ATP6V1G2*	M1	<1%	8.596[0.965;76.602]	5.40E-02	1872|1|0	508475|57|0	0.00006	6:31153649:G:A	391758	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*ATP6V1G2*	M3	<1%	8.596[0.965;76.602]	5.40E-02	1872|1|0	508475|57|0	0.00006	6:31153649:G:A	391758	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF6*	M1	<1%	5.025[0.971;25.993]	5.40E-02	2016|2|0	525975|252|0	0.00024	9:133270015:A:C	61853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*MYDGF*	M3	<1%	0.343[0.115;1.024]	5.50E-02	2085|0|0	534469|496|0	0.00046	19:4719431:G:A	61427	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*XCR1*	M1	<1%	3.068[0.967;9.733]	5.70E-02	2017|3|0	525432|333|0	0.00032	3:45859597:C:T	161348	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*C6orf15*	M3	<1%	3.003[0.965;9.351]	5.80E-02	2016|4|0	525465|299|1	0.00029	6:31153649:G:A	42269	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*LARS2*	M3	<1%	1.355[0.987;1.861]	6.00E-02	2036|48|1	524945|9982|38	0.00941	3:45859597:C:T	465144	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*PRRC2A*	M3	<1%	0.716[0.505;1.016]	6.10E-02	2063|22|0	524933|10025|7	0.00937	6:31153649:G:A	469140	34
COVID19 positive hospitalized vs COVID19 negative or unknown	*LIMD1*	M3	<1%	2.202[0.962;5.038]	6.20E-02	2079|6|0	534053|912|0	0.00085	3:45859597:C:T	264718	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*FPR1*	M1	<1%	9.521[0.887;102.209]	6.30E-02	2019|1|0	525731|34|0	0.00003	19:51739497	6444	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC14*	M3	<1%	3.535[0.936;13.349]	6.30E-02	2003|2|0	526273|179|18	0.00021	19:51739497	96143	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CYBA*	M3	<1%	2.843[0.930;8.693]	6.70E-02	2080|5|0	534405|560|0	0.00053	16:89117727	474375	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*OLIG1*	M1	<1%	7.354[0.856;63.204]	6.90E-02	1872|1|0	508454|78|0	0.00008	21:33252612:A:G	182366	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*OLIG1*	M3	<1%	7.354[0.856;63.204]	6.90E-02	1872|1|0	508454|78|0	0.00008	21:33252612:A:G	182366	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF615*	M1	<1%	0.368[0.121;1.117]	7.80E-02	2085|0|0	534154|810|1	0.00076	19:51739497	253382	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF615*	M3	<1%	0.368[0.121;1.117]	7.80E-02	2085|0|0	534154|810|1	0.00076	19:51739497	253382	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*KDM4B*	M3	<1%	2.146[0.916;5.028]	7.90E-02	2077|8|0	533186|1778|1	0.00166	19:4719431:G:A	313459	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*CPNE7*	M1	<1%	2.509[0.871;7.222]	8.80E-02	2079|6|0	534223|742|0	0.0007	16:89117727	458170	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*DBH*	M3	<1%	0.824[0.657;1.033]	9.30E-02	2021|64|0	514043|20887|35	0.01957	9:133270015:A:C	366356	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF1*	M1	<1%	1.734[0.905;3.321]	9.70E-02	2075|10|0	533511|1454|0	0.00136	9:133270015:A:C	81897	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CTU2*	M1	<1%	2.046[0.868;4.822]	1.00E-01	2076|9|0	533716|1247|2	0.00117	16:89117727	411197	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*FEM1A*	M1	<1%	3.778[0.670;21.285]	1.30E-01	2015|3|0	525914|313|0	0.0003	19:4719431:G:A	72423	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*FEM1A*	M3	<1%	3.778[0.670;21.285]	1.30E-01	2015|3|0	525914|313|0	0.0003	19:4719431:G:A	72423	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*LZTFL1*	M3	<1%	2.578[0.756;8.800]	1.30E-01	2082|3|0	534504|460|1	0.00043	3:45859597:C:T	33284	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF2*	M3	<1%	0.471[0.176;1.262]	1.30E-01	2084|1|0	534038|927|0	0.00086	9:133270015:A:C	86577	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*ARRDC5*	M3	<1%	2.513[0.744;8.487]	1.40E-01	2080|5|0	534263|702|0	0.00066	19:4719431:G:A	171614	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*FLOT1*	M3	<1%	1.969[0.802;4.836]	1.40E-01	2077|8|0	533722|1242|1	0.00117	6:31153649:G:A	425534	26
COVID19 positive hospitalized vs COVID19 negative or unknown	*IGLON5*	M1	<1%	19.079[0.389;936.241]	1.40E-01	1872|1|0	508445|87|0	0.00009	19:51739497	427650	32
COVID19 positive hospitalized vs COVID19 negative or unknown	*SLC6A20*	M1	<1%	0.462[0.161;1.328]	1.50E-01	2085|0|0	534061|904|0	0.00084	3:45859597:C:T	101161	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*MAT2B*	M3	<1%	0.473[0.168;1.330]	1.60E-01	2084|1|0	534078|887|0	0.00083	5:163300447	202947	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*SARDH*	M3	<1%	1.293[0.905;1.848]	1.60E-01	2050|34|1	528071|6891|3	0.00645	9:133270015:A:C	393873	25
COVID19 positive hospitalized vs COVID19 negative or unknown	*TSC1*	M3	<1%	0.741[0.490;1.121]	1.60E-01	2069|16|0	528190|6768|7	0.00633	9:133270015:A:C	373781	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*MUC21*	M1	<1%	0.367[0.086;1.555]	1.70E-01	2020|0|0	525263|501|1	0.00048	6:31153649:G:A	169691	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*MUC21*	M3	<1%	0.367[0.086;1.555]	1.70E-01	2020|0|0	525263|501|1	0.00048	6:31153649:G:A	169691	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*PLIN5*	M1	<1%	0.486[0.172;1.374]	1.70E-01	2084|1|0	534032|931|2	0.00087	19:4719431:G:A	195904	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*PLIN5*	M3	<1%	0.486[0.172;1.374]	1.70E-01	2084|1|0	534032|931|2	0.00087	19:4719431:G:A	195904	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*LIMD1*	M1	<1%	11.539[0.303;439.203]	1.90E-01	1872|1|0	508431|101|0	0.0001	3:45859597:C:T	264718	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*MVD*	M1	<1%	0.362[0.078;1.673]	1.90E-01	1938|0|0	517333|399|0	0.00038	16:89117727	465203	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*NCR3*	M3	<1%	0.373[0.086;1.608]	1.90E-01	2020|0|0	525351|414|0	0.00039	6:31153649:G:A	435417	30
COVID19 positive hospitalized vs COVID19 negative or unknown	*RNF166*	M3	<1%	2.052[0.696;6.046]	1.90E-01	2016|4|0	525167|598|0	0.00057	16:89117727	420160	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*SACM1L*	M1	<1%	3.293[0.554;19.585]	1.90E-01	1937|1|0	517584|148|0	0.00014	3:45859597:C:T	170132	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCDC94*	M1	<1%	3.763[0.497;28.456]	2.00E-01	2019|1|0	525606|159|0	0.00015	19:4719431:G:A	472285	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*SACM1L*	M3	<1%	1.982[0.690;5.692]	2.00E-01	2080|5|0	534178|786|1	0.00074	3:45859597:C:T	170132	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAPPC2L*	M1	<1%	0.759[0.498;1.158]	2.00E-01	2069|16|0	528171|6783|11	0.00635	16:89117727	260577	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF616*	M1	<1%	0.493[0.166;1.465]	2.00E-01	2004|1|0	525530|940|0	0.00089	19:51739497	375320	28
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF616*	M3	<1%	0.493[0.166;1.465]	2.00E-01	2004|1|0	525530|940|0	0.00089	19:51739497	375320	28
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF836*	M1	<1%	0.363[0.076;1.725]	2.00E-01	2085|0|0	534615|350|0	0.00033	19:51739497	415374	31
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF836*	M3	<1%	0.363[0.076;1.725]	2.00E-01	2085|0|0	534615|350|0	0.00033	19:51739497	415374	31
COVID19 positive hospitalized vs COVID19 negative or unknown	*CEACAM18*	M1	<1%	0.365[0.075;1.773]	2.10E-01	2005|0|0	526042|428|0	0.0004	19:51739497	260855	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*CEACAM18*	M3	<1%	0.365[0.075;1.773]	2.10E-01	2005|0|0	526042|428|0	0.0004	19:51739497	260855	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*DNAJC28*	M1	<1%	0.561[0.228;1.381]	2.10E-01	2083|2|0	533837|1128|0	0.00105	21:33252612:A:G	235614	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*APRT*	M3	<1%	0.502[0.168;1.501]	2.20E-01	2084|1|0	534131|834|0	0.00078	16:89117727	308030	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*BAG6*	M3	<1%	0.713[0.416;1.224]	2.20E-01	2076|9|0	531625|3337|3	0.00312	6:31153649:G:A	485481	36
COVID19 positive hospitalized vs COVID19 negative or unknown	*HMMR*	M3	<1%	0.688[0.377;1.254]	2.20E-01	2078|7|0	532229|2730|6	0.00256	5:163300447	160245	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*SLC6A20*	M3	<1%	0.721[0.428;1.216]	2.20E-01	2076|9|0	531236|3727|2	0.00348	3:45859597:C:T	101161	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*SPAC49*	M1	<1%	0.368[0.075;1.806]	2.20E-01	2085|0|0	534523|440|2	0.00041	9:133270015:A:C	386068	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*VARS2*	M1	<1%	0.768[0.503;1.174]	2.20E-01	2069|16|0	529226|5729|10	0.00537	6:31153649:G:A	239238	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF841*	M1	<1%	0.562[0.225;1.399]	2.20E-01	2083|2|0	533694|1271|0	0.00119	19:51739497	325609	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF841*	M3	<1%	0.562[0.225;1.399]	2.20E-01	2083|2|0	533694|1271|0	0.00119	19:51739497	325609	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*DDR1*	M1	<1%	0.365[0.071;1.871]	2.30E-01	1938|0|0	517314|418|0	0.0004	6:31153649:G:A	268430	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*FYCO1*	M3	<1%	1.270[0.862;1.871]	2.30E-01	2055|30|0	527455|7494|16	0.00703	3:45859597:C:T	62167	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNGR2*	M1	<1%	8.396[0.261;270.048]	2.30E-01	1872|1|0	508441|91|0	0.00009	21:33252612:A:G	150931	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*TCF19*	M3	<1%	0.506[0.167;1.534]	2.30E-01	2084|1|0	534099|865|1	0.00081	6:31153649:G:A	5820	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*VARS2*	M3	<1%	0.820[0.593;1.135]	2.30E-01	2055|30|0	525693|9261|11	0.00867	6:31153649:G:A	239238	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M1	<1%	2.077[0.620;6.961]	2.40E-01	2082|3|0	534277|688|0	0.00064	21:33252612:A:G	10690	1

COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF6*	M3	<1%	1.442[0.785;2.651]	2.40E-01	2071|14|0	532573|2388|4	0.00224	9:133270015:A:C	61853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*AC074141.1*	M1	<1%	0.515[0.167;1.587]	2.50E-01	2084|1|0	534249|715|1	0.00067	19:51739497	133034	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*AC074141.1*	M3	<1%	0.515[0.167;1.587]	2.50E-01	2084|1|0	534249|715|1	0.00067	19:51739497	133034	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*MED22*	M1	<1%	2.725[0.493;15.068]	2.50E-01	1872|1|0	508339|193|0	0.00019	9:133270015:A:C	71489	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCNG1*	M3	<1%	2.100[0.575;7.670]	2.60E-01	2081|4|0	534370|595|0	0.00056	5:163300447	138809	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*MYDGF*	M1	<1%	0.315[0.042;2.346]	2.60E-01	2085|0|0	534773|192|0	0.00018	19:4719431:G:A	61427	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*NCR3*	M1	<1%	0.363[0.063;2.083]	2.60E-01	1873|0|0	508231|301|0	0.00029	6:31153649:G:A	435417	30
COVID19 positive hospitalized vs COVID19 negative or unknown	*SON*	M3	<1%	1.154[0.897;1.483]	2.60E-01	2014|70|1	518373|16570|22	0.01553	21:33252612:A:G	290480	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M3	<1%	1.968[0.598;6.469]	2.70E-01	2082|3|0	534253|712|0	0.00067	21:33252612:A:G	10690	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*SPG7*	M1	<1%	1.418[0.762;2.638]	2.70E-01	2075|10|0	532986|1978|1	0.00185	16:89117727	390690	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*GALNS*	M1	<1%	0.370[0.061;2.257]	2.80E-01	1953|0|0	516724|303|0	0.00029	16:89117727	303289	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*POU5F1*	M3	<1%	0.363[0.057;2.295]	2.80E-01	1873|0|0	508235|297|0	0.00029	6:31153649:G:A	10951	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC8*	M1	<1%	2.359[0.503;11.052]	2.80E-01	2017|3|0	525367|398|0	0.00038	19:51739497	287119	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF432*	M1	<1%	1.745[0.629;4.839]	2.80E-01	2078|7|0	533544|1421|0	0.00133	19:51739497	294222	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF432*	M3	<1%	1.745[0.629;4.839]	2.80E-01	2078|7|0	533544|1421|0	0.00133	19:51739497	294222	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*DONSON*	M3	<1%	1.265[0.809;1.979]	3.00E-01	2061|24|0	530103|4855|7	0.00456	21:33252612:A:G	325694	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF2*	M1	<1%	0.532[0.161;1.757]	3.00E-01	2084|1|0	534311|654|0	0.00061	9:133270015:A:C	86577	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF4*	M1	<1%	5.574[0.219;142.075]	3.00E-01	1937|1|0	517635|96|1	0.0001	9:133270015:A:C	93448	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*IGLON5*	M3	<1%	1.781[0.591;5.367]	3.10E-01	2080|5|0	534127|838|0	0.00078	19:51739497	427650	32
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC8*	M3	<1%	2.209[0.485;10.070]	3.10E-01	2082|3|0	534553|412|0	0.00039	19:51739497	287119	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*ADAMTSL2*	M3	<1%	0.674[0.308;1.477]	3.20E-01	2081|4|0	533538|1420|7	0.00134	9:133270015:A:C	264725	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*ARRDC5*	M1	<1%	4.900[0.209;114.787]	3.20E-01	1872|1|0	508406|126|0	0.00012	19:4719431:G:A	171614	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*GF11B*	M3	<1%	0.761[0.444;1.304]	3.20E-01	2075|10|0	531725|3238|2	0.00303	9:133270015:A:C	283337	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*LIM2*	M3	<1%	1.580[0.643;3.881]	3.20E-01	2078|7|0	533775|1190|0	0.00111	19:51739497	359297	25
COVID19 positive hospitalized vs COVID19 negative or unknown	*OBP2B*	M1	<1%	1.214[0.828;1.778]	3.20E-01	2053|32|0	528194|6771|0	0.00633	9:133270015:A:C	64687	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*OBP2B*	M3	<1%	1.214[0.828;1.778]	3.20E-01	2053|32|0	528194|6771|0	0.00633	9:133270015:A:C	64687	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*PRRC2A*	M1	<1%	0.638[0.262;1.553]	3.20E-01	1870|3|0	505561|2971|0	0.00291	6:31153649:G:A	469140	34
COVID19 positive hospitalized vs COVID19 negative or unknown	*CDT1*	M1	<1%	2.121[0.474;9.487]	3.30E-01	2015|3|0	525792|435|0	0.00041	16:89117727	313896	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*RPL7A*	M3	<1%	0.364[0.048;2.778]	3.30E-01	1953|0|0	516804|223|0	0.00021	9:133270015:A:C	78228	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*TCF19*	M1	<1%	0.369[0.050;2.706]	3.30E-01	1938|0|0	517437|294|1	0.00028	6:31153649:G:A	5820	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*XCR1*	M3	<1%	1.753[0.566;5.428]	3.30E-01	2081|4|0	534290|675|0	0.00063	3:45859597:C:T	161348	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CDSN*	M3	<1%	0.680[0.310;1.494]	3.40E-01	2074|11|0	531401|3563|1	0.00333	6:31153649:G:A	37625	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CEL*	M1	<1%	0.802[0.513;1.256]	3.40E-01	2070|15|0	530001|4944|20	0.00465	9:133270015:A:C	208022	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCR9*	M1	<1%	0.354[0.041;3.080]	3.50E-01	1938|0|0	517545|187|0	0.00018	3:45859597:C:T	35336	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*CTU2*	M3	<1%	1.180[0.834;1.670]	3.50E-01	2047|38|0	526415|8544|6	0.008	16:89117727	411197	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*SPACA9*	M3	<1%	0.689[0.317;1.498]	3.50E-01	2081|4|0	533295|1668|2	0.00156	9:133270015:A:C	386068	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*CEL*	M3	<1%	0.832[0.564;1.229]	3.60E-01	2064|21|0	528589|6355|21	0.00598	9:133270015:A:C	208022	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*CRYZL1*	M1	<1%	0.363[0.042;3.132]	3.60E-01	1938|0|0	517520|212|0	0.0002	21:33252612:A:G	337178	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*FAM163B*	M3	<1%	1.436[0.647;3.191]	3.70E-01	2066|19|0	530396|4569|0	0.00427	9:133270015:A:C	309006	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*MPND*	M1	<1%	0.376[0.044;3.228]	3.70E-01	2020|0|0	525540|224|1	0.00021	19:4719431:G:A	375838	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*C21orf62*	M1	<1%	0.362[0.038;3.417]	3.80E-01	1938|0|0	517567|165|0	0.00016	21:33252612:A:G	458851	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*C21orf62*	M3	<1%	0.362[0.038;3.417]	3.80E-01	1938|0|0	517567|165|0	0.00016	21:33252612:A:G	458851	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*PIEZO1*	M1	<1%	0.722[0.350;1.488]	3.80E-01	2080|5|0	533243|1722|0	0.00161	16:89117727	402123	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*ACSF3*	M3	<1%	0.874[0.642;1.189]	3.90E-01	2048|37|0	524213|10735|17	0.01006	16:89117727	17046	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*HMMR*	M1	<1%	0.722[0.342;1.522]	3.90E-01	2080|5|0	533239|1721|5	0.00162	5:163300447	160245	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*SHD*	M3	<1%	1.511[0.585;3.902]	3.90E-01	2079|6|0	533918|1045|2	0.00098	19:4719431:G:A	439368	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M1	<1%	3.730[0.189;73.610]	3.90E-01	1872|1|0	508368|164|0	0.00016	19:4719431:G:A	96807	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	<1%	3.657[0.188;71.218]	3.90E-01	1872|1|0	508365|167|0	0.00016	19:4719431:G:A	96807	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF1*	M3	<1%	1.308[0.702;2.439]	4.00E-01	2072|13|0	532627|2338|0	0.00219	9:133270015:A:C	81897	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CXCR6*	M1	<1%	0.364[0.034;3.941]	4.10E-01	1940|0|0	517072|198|0	0.00019	3:45859597:C:T	86884	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*DDX39B*	M3	<1%	0.367[0.034;3.973]	4.10E-01	1873|0|0	508265|267|0	0.00026	6:31153649:G:A	376784	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*IL17C*	M3	<1%	1.666[0.496;5.595]	4.10E-01	2081|4|0	534261|704|0	0.00066	16:89117727	479086	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*UBXN6*	M1	<1%	0.368[0.034;3.984]	4.10E-01	2020|0|0	525583|182|0	0.00017	19:4719431:G:A	273934	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*PPP1R18*	M1	<1%	0.365[0.031;4.278]	4.20E-01	1873|0|0	508356|176|0	0.00017	6:31153649:G:A	476381	35
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF614*	M1	<1%	2.130[0.339;13.393]	4.20E-01	2083|2|0	534709|256|0	0.00024	19:51739497	273639	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF614*	M3	<1%	2.130[0.339;13.393]	4.20E-01	2083|2|0	534709|256|0	0.00024	19:51739497	273639	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*ETFB*	M3	<1%	1.329[0.655;2.696]	4.30E-01	2077|8|0	533213|1751|1	0.00164	19:51739497	394287	29
COVID19 positive hospitalized vs COVID19 negative or unknown	*ACSF3*	M1	<1%	0.683[0.258;1.808]	4.40E-01	2082|3|0	534093|872|0	0.00081	16:89117727	17046	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*ANKRD11*	M3	<1%	1.168[0.788;1.733]	4.40E-01	2056|29|0	528339|6623|3	0.0062	16:89117727	150750	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*DNAJC28*	M3	<1%	0.762[0.384;1.512]	4.40E-01	2079|6|0	533031|1934|0	0.00181	21:33252612:A:G	235614	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*FYCO1*	M1	<1%	1.425[0.575;3.534]	4.40E-01	2080|5|0	533865|1098|2	0.00103	3:45859597:C:T	62167	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*GALNS*	M3	<1%	0.747[0.357;1.563]	4.40E-01	2080|5|0	533141|1823|1	0.0017	16:89117727	303289	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNGR2*	M3	<1%	3.072[0.176;53.618]	4.40E-01	1872|1|0	508406|126|0	0.00012	21:33252612:A:G	150931	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*PLIN3*	M3	<1%	0.591[0.154;2.274]	4.40E-01	2084|1|0	534513|451|1	0.00042	19:4719431:G:A	119760	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*PLIN4*	M3	<1%	1.203[0.756;1.912]	4.40E-01	2064|21|0	530811|4133|21	0.00391	19:4719431:G:A	214973	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAPPC2L*	M3	<1%	0.856[0.575;1.273]	4.40E-01	2064|21|0	527447|7504|14	0.00703	16:89117727	260577	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*ADAMTSL2*	M1	<1%	0.727[0.317;1.669]	4.50E-01	2081|4|0	533744|1214|7	0.00115	9:133270015:A:C	264725	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*GART*	M1	<1%	1.393[0.591;3.285]	4.50E-01	2078|7|0	533417|1548|0	0.00145	21:33252612:A:G	251511	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*IL10RB*	M1	<1%	2.965[0.174;50.555]	4.50E-01	1937|1|0	517584|148|0	0.00014	21:33252612:A:G	13853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*SLC2A6*	M1	<1%	0.377[0.030;4.670]	4.50E-01	2085|0|0	534801|163|1	0.00015	9:133270015:A:C	202005	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF649*	M1	<1%	0.367[0.027;4.993]	4.50E-01	1873|0|0	508363|169|0	0.00017	19:51739497	151120	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF649*	M3	<1%	0.367[0.027;4.993]	4.50E-01	1873|0|0	508363|169|0	0.00017	19:51739497	151120	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*AIF1*	M1	<1%	0.364[0.025;5.368]	4.60E-01	1938|0|0	517587|145|0	0.00014	6:31153649:G:A	461680	32
COVID19 positive hospitalized vs COVID19 negative or unknown	*SEMA6B*	M1	<1%	0.359[0.023;5.521]	4.60E-01	1873|0|0	508407|125|0	0.00012	19:4719431:G:A	176518	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*SEMA6B*	M3	<1%	0.359[0.023;5.521]	4.60E-01	1873|0|0	508407|125|0	0.00012	19:4719431:G:A	176518	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*EBI3*	M1	<1%	0.366[0.023;5.774]	4.70E-01	1873|0|0	508388|144|0	0.00014	19:4719431:G:A	489881	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*FLOT1*	M1	<1%	0.365[0.023;5.722]	4.70E-01	1873|0|0	508397|135|0	0.00013	6:31153649:G:A	425534	26
COVID19 positive hospitalized vs COVID19 negative or unknown	*MED22*	M3	<1%	0.600[0.150;2.401]	4.70E-01	2084|1|0	534484|481|0	0.00045	9:133270015:A:C	71489	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*NKG7*	M3	<1%	1.921[0.322;11.460]	4.70E-01	1871|2|0	508207|325|0	0.00032	19:51739497	367721	26
COVID19 positive hospitalized vs COVID19 negative or unknown	*SLC2A6*	M3	<1%	1.403[0.555;3.542]	4.70E-01	2079|6|0	533752|1212|1	0.00114	9:133270015:A:C	202005	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*C19orf84*	M1	<1%	0.363[0.021;6.289]	4.90E-01	1770|0|0	407837|141|0	0.00017	19:51739497	350514	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*C19orf84*	M3	<1%	0.363[0.021;6.289]	4.90E-01	1770|0|0	407837|141|0	0.00017	19:51739497	350514	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*LZTFL1*	M1	<1%	0.368[0.022;6.171]	4.90E-01	1873|0|0	508386|146|0	0.00014	3:45859597:C:T	33284	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*TMIGD2*	M1	<1%	1.872[0.319;11.005]	4.90E-01	2016|2|0	525931|295|1	0.00028	19:4719431:G:A	426833	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*TMIGD2*	M3	<1%	1.872[0.319;11.005]	4.90E-01	2016|2|0	525931|295|1	0.00028	19:4719431:G:A	426833	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*GART*	M3	<1%	1.178[0.728;1.903]	5.00E-01	2065|20|0	530814|4149|2	0.00389	21:33252612:A:G	251511	9

COVID19 positive hospitalized vs COVID19 negative or unknown	*LTB*	M3	<1%	0.359[0.018;7.128]	5.00E-01	1873|0|0	508445|87|0	0.00009	6:31153649:G:A	427059	27
COVID19 positive hospitalized vs COVID19 negative or unknown	*NUDCD2*	M3	<1%	0.607[0.142;2.598]	5.00E-01	2084|1|0	534582|383|0	0.00036	5:163300447	153519	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*SURF4*	M3	<1%	0.612[0.149;2.513]	5.00E-01	2084|1|0	534492|472|1	0.00044	9:133270015:A:C	93448	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*C6orf15*	M1	<1%	0.370[0.019;7.362]	5.10E-01	1873|0|0	508407|124|1	0.00012	6:31153649:G:A	42269	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*CDT1*	M3	<1%	0.840[0.500;1.412]	5.10E-01	2073|12|0	532038|2920|7	0.00274	16:89117727	313896	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*FPR2*	M1	<1%	0.365[0.019;7.103]	5.10E-01	1953|0|0	516947|80|0	0.00008	19:51739497	29161	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*FPR2*	M3	<1%	0.365[0.019;7.103]	5.10E-01	1953|0|0	516947|80|0	0.00008	19:51739497	29161	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*MPND*	M3	<1%	1.146[0.765;1.717]	5.10E-01	2059|25|1	528772|6178|15	0.0058	19:4719431:G:A	375838	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*GTF3C5*	M3	<1%	1.236[0.644;2.372]	5.20E-01	2074|11|0	532496|2469|0	0.00231	9:133270015:A:C	239004	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*MVD*	M3	<1%	0.778[0.361;1.676]	5.20E-01	2080|5|0	533277|1687|1	0.00158	16:89117727	465203	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*CBFA2T3*	M1	<1%	2.336[0.164;33.240]	5.30E-01	1872|1|0	508348|183|1	0.00018	16:89117727	240752	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCNG1*	M1	<1%	0.370[0.017;7.948]	5.30E-01	2020|0|0	525664|101|0	0.0001	5:163300447	138809	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*IL17C*	M1	<1%	0.364[0.016;8.237]	5.30E-01	1873|0|0	508415|117|0	0.00011	16:89117727	479086	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*AC018755.18*	M3	<1%	1.134[0.757;1.697]	5.40E-01	2058|27|0	528870|6077|18	0.00572	19:51739497	127267	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*HAS1*	M3	<1%	1.169[0.709;1.925]	5.40E-01	2067|18|0	530804|4159|2	0.00389	19:51739497	26071	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*PLIN3*	M1	<1%	0.640[0.151;2.712]	5.40E-01	2084|1|0	534575|389|1	0.00036	19:4719431:G:A	119760	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*APRT*	M1	<1%	0.637[0.147;2.755]	5.50E-01	1939|1|0	516800|470|0	0.00045	16:89117727	308030	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*FPR3*	M3	<1%	0.379[0.016;9.247]	5.50E-01	1940|0|0	517201|69|0	0.00007	19:51739497	84251	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF577*	M1	<1%	0.710[0.232;2.175]	5.50E-01	2083|2|0	534235|729|1	0.00068	19:51739497	133034	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF577*	M3	<1%	0.710[0.232;2.175]	5.50E-01	2083|2|0	534235|729|1	0.00068	19:51739497	133034	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCR3*	M3	<1%	0.839[0.467;1.509]	5.60E-01	2076|9|0	532705|2252|8	0.00212	3:45859597:C:T	404806	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*REXO4*	M1	<1%	1.410[0.440;4.521]	5.60E-01	2081|4|0	534520|442|3	0.00042	9:133270015:A:C	136937	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*ABO*	M1	<1%	1.163[0.694;1.949]	5.70E-01	2068|17|0	531205|3752|8	0.00352	9:133270015:A:C	14414	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*ABO*	M3	<1%	1.163[0.694;1.949]	5.70E-01	2068|17|0	531205|3752|8	0.00352	9:133270015:A:C	14414	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*CRYZL1*	M3	<1%	0.755[0.288;1.982]	5.70E-01	2082|3|0	533923|1041|1	0.00097	21:33252612:A:G	337178	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*DPP9*	M1	<1%	0.364[0.011;12.326]	5.70E-01	1938|0|0	517629|103|0	0.0001	19:4719431:G:A	42868	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*GTF2H4*	M1	<1%	0.648[0.147;2.863]	5.70E-01	1872|1|0	508061|471|0	0.00046	6:31153649:G:A	244613	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*GTF2H4*	M3	<1%	0.648[0.147;2.863]	5.70E-01	1872|1|0	508061|471|0	0.00046	6:31153649:G:A	244613	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*NFKBIL1*	M1	<1%	0.362[0.010;12.546]	5.70E-01	1938|0|0	517626|106|0	0.0001	6:31153649:G:A	394045	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAP2*	M1	<1%	0.647[0.146;2.879]	5.70E-01	2084|1|0	534556|408|1	0.00038	19:4719431:G:A	395299	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAP2*	M3	<1%	0.647[0.146;2.879]	5.70E-01	2084|1|0	534556|408|1	0.00038	19:4719431:G:A	395299	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*AC018755.18*	M1	<1%	1.121[0.745;1.688]	5.80E-01	2059|26|0	529089|5858|18	0.00551	19:51739497	127267	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*DDR1*	M3	<1%	0.897[0.612;1.314]	5.80E-01	2061|24|0	528177|6786|2	0.00634	6:31153649:G:A	268430	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*GTF3C5*	M1	<1%	1.613[0.302;8.614]	5.80E-01	2018|2|0	525364|401|0	0.00038	9:133270015:A:C	239004	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*IER3*	M3	<1%	0.366[0.011;12.404]	5.80E-01	1940|0|0	517178|92|0	0.00009	6:31153649:G:A	409714	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*RPL13*	M1	<1%	0.386[0.014;11.051]	5.80E-01	2020|0|0	525710|55|0	0.00005	16:89117727	443232	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*RPL13*	M3	<1%	0.386[0.014;11.051]	5.80E-01	2020|0|0	525710|55|0	0.00005	16:89117727	443232	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*CXCR6*	M3	<1%	1.374[0.439;4.303]	5.90E-01	2082|3|0	533961|1004|0	0.00094	3:45859597:C:T	86884	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*DDX39B*	M1	<1%	0.369[0.010;13.799]	5.90E-01	1873|0|0	508388|144|0	0.00014	6:31153649:G:A	376784	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*EBI3*	M3	<1%	0.659[0.147;2.957]	5.90E-01	2084|1|0	534577|387|1	0.00036	19:4719431:G:A	489881	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*HLA-C*	M1	<1%	0.819[0.399;1.682]	5.90E-01	1932|6|0	515869|1859|4	0.0018	6:31153649:G:A	115519	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*HLA-C*	M3	<1%	0.819[0.399;1.682]	5.90E-01	1932|6|0	515869|1859|4	0.0018	6:31153649:G:A	115519	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*SNAI3*	M1	<1%	2.035[0.154;26.820]	5.90E-01	1937|1|0	517625|104|3	0.00011	16:89117727	439280	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*CYBA*	M1	<1%	0.365[0.009;15.232]	6.00E-01	1873|0|0	508439|93|0	0.00009	16:89117727	474375	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*LTA*	M3	<1%	0.370[0.009;15.194]	6.00E-01	1873|0|0	508450|82|0	0.00008	6:31153649:G:A	419093	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC10*	M3	<1%	1.257[0.533;2.964]	6.00E-01	2080|5|0	532691|2274|0	0.00212	19:51739497	328399	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*ETFB*	M1	<1%	0.382[0.010;15.023]	6.10E-01	2018|0|0	526137|90|0	0.00009	19:51739497	394287	29
COVID19 positive hospitalized vs COVID19 negative or unknown	*IER3*	M1	<1%	0.365[0.008;17.529]	6.10E-01	1873|0|0	508462|70|0	0.00007	6:31153649:G:A	409714	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*MAT2B*	M1	<1%	0.365[0.008;17.788]	6.10E-01	1873|0|0	508463|69|0	0.00007	5:163300447	202947	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*RPL7A*	M1	<1%	0.364[0.007;18.601]	6.10E-01	1873|0|0	508464|68|0	0.00007	9:133270015:A:C	78228	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*TMEM50B*	M3	<1%	1.489[0.318;6.964]	6.10E-01	2004|1|0	526117|353|0	0.00033	21:33252612:A:G	198205	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCR9*	M3	<1%	0.845[0.435;1.640]	6.20E-01	2075|10|0	531749|3216|0	0.003	3:45859597:C:T	35336	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*PIEZO1*	M3	<1%	0.954[0.793;1.149]	6.20E-01	1973|111|1	504609|30275|81	0.02844	16:89117727	402123	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC1.1*	M1	<1%	1.211[0.569;2.576]	6.20E-01	2010|8|0	524449|1772|6	0.0017	19:51739497	475425	34
COVID19 positive hospitalized vs COVID19 negative or unknown	*TMEM8C*	M1	<1%	0.366[0.007;19.640]	6.20E-01	1873|0|0	508459|73|0	0.00007	9:133270015:A:C	244620	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*ANKRD11*	M1	<1%	0.370[0.006;21.174]	6.30E-01	1873|0|0	508426|106|0	0.0001	16:89117727	150750	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*HLA-B*	M1	<1%	0.370[0.006;21.195]	6.30E-01	1873|0|0	508450|82|0	0.00008	6:31153649:G:A	200833	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*HLA-B*	M3	<1%	0.370[0.006;21.195]	6.30E-01	1873|0|0	508450|82|0	0.00008	6:31153649:G:A	200833	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*LTB*	M1	<1%	0.364[0.006;22.319]	6.30E-01	1873|0|0	508475|57|0	0.00006	6:31153649:G:A	427059	27
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC1.1*	M3	<1%	1.204[0.567;2.557]	6.30E-01	2077|8|0	533180|1779|6	0.00167	19:51739497	475425	34
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M3	<1%	0.756[0.234;2.444]	6.40E-01	2083|2|0	534219|746|0	0.0007	21:33252612:A:G	72443	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*NRM*	M1	<1%	1.796[0.152;21.204]	6.40E-01	1952|1|0	516825|202|0	0.0002	6:31153649:G:A	464989	33
COVID19 positive hospitalized vs COVID19 negative or unknown	*GF11B*	M1	<1%	0.367[0.004;30.523]	6.60E-01	1873|0|0	508466|66|0	0.00006	9:133270015:A:C	283337	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*PLIN4*	M1	<1%	1.140[0.639;2.033]	6.60E-01	2072|13|0	532007|2949|9	0.00277	19:4719431:G:A	214973	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*SON*	M1	<1%	0.364[0.004;34.635]	6.60E-01	1940|0|0	517207|63|0	0.00006	21:33252612:A:G	290480	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*HAS1*	M1	<1%	1.189[0.532;2.654]	6.70E-01	2078|7|0	533219|1745|1	0.00163	19:51739497	26071	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*LRG1*	M3	<1%	1.270[0.427;3.778]	6.70E-01	2083|2|0	534605|360|0	0.00034	19:4719431:G:A	181492	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC6*	M1	<1%	0.708[0.143;3.510]	6.70E-01	1872|1|0	507687|845|0	0.00083	19:51739497	219416	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC6*	M3	<1%	0.708[0.143;3.510]	6.70E-01	1872|1|0	507687|845|0	0.00083	19:51739497	219416	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*TNF*	M3	<1%	1.319[0.364;4.770]	6.70E-01	1950|3|0	516388|639|0	0.00062	6:31153649:G:A	422092	25
COVID19 positive hospitalized vs COVID19 negative or unknown	*LST1*	M1	<1%	0.366[0.003;43.447]	6.80E-01	1873|0|0	508483|49|0	0.00005	6:31153649:G:A	433650	29
COVID19 positive hospitalized vs COVID19 negative or unknown	*LST1*	M3	<1%	0.366[0.003;43.447]	6.80E-01	1873|0|0	508483|49|0	0.00005	6:31153649:G:A	433650	29
COVID19 positive hospitalized vs COVID19 negative or unknown	*MCCD1*	M1	<1%	1.676[0.149;18.821]	6.80E-01	1872|1|0	508364|168|0	0.00017	6:31153649:G:A	375365	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*MCCD1*	M3	<1%	1.676[0.149;18.821]	6.80E-01	1872|1|0	508364|168|0	0.00017	6:31153649:G:A	375365	19
COVID19 positive hospitalized vs COVID19 negative or unknown	*TNFAIP8L1*	M1	<1%	0.367[0.003;43.093]	6.80E-01	1873|0|0	508485|47|0	0.00005	19:4719431:G:A	67562	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCR1*	M1	<1%	0.364[0.002;56.469]	6.90E-01	1873|0|0	508498|34|0	0.00003	3:45859597:C:T	343648	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*LIM2*	M1	<1%	0.370[0.003;49.414]	6.90E-01	1940|0|0	517211|59|0	0.00006	19:51739497	359297	25
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF613*	M3	<1%	1.380[0.280;6.797]	6.90E-01	2083|2|0	534542|423|0	0.0004	19:51739497	196723	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*MICA*	M1	<1%	1.113[0.628;1.974]	7.10E-01	2072|13|0	531757|3199|9	0.00301	6:31153649:G:A	249983	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*MICA*	M3	<1%	1.113[0.628;1.974]	7.10E-01	2072|13|0	531757|3199|9	0.00301	6:31153649:G:A	249983	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF778*	M1	<1%	0.826[0.298;2.288]	7.10E-01	2082|3|0	533989|974|2	0.00091	16:89117727	103400	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF778*	M3	<1%	0.826[0.298;2.288]	7.10E-01	2082|3|0	533989|974|2	0.00091	16:89117727	103400	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*FPR1*	M3	<1%	0.796[0.234;2.707]	7.20E-01	2083|2|0	534362|603|0	0.00056	19:51739497	6444	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*PSORS1C2*	M3	<1%	1.214[0.419;3.516]	7.20E-01	2016|4|0	524628|1136|1	0.00108	6:31153649:G:A	15699	4
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF613*	M1	<1%	0.741[0.144;3.824]	7.20E-01	2084|1|0	534564|401|0	0.00037	19:51739497	196723	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*DONSON*	M1	<1%	1.206[0.418;3.480]	7.30E-01	2081|4|0	534292|671|2	0.00063	21:33252612:A:G	325694	11

COVID19 positive hospitalized vs COVID19 negative or unknown	*FSD1*	M1	<1%	0.369[0.001;117.744]	7.30E-01	1873|0|0	508494|38|0	0.00004	19:4719431:G:A	414685	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*GBGT1*	M3	<1%	1.049[0.804;1.368]	7.30E-01	2027|57|1	521986|12948|31	0.01217	9:133270015:A:C	116439	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC12*	M1	<1%	1.182[0.460;3.036]	7.30E-01	2080|5|0	533981|982|2	0.00092	19:51739497	247857	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC12*	M3	<1%	1.179[0.459;3.029]	7.30E-01	2080|5|0	533980|983|2	0.00092	19:51739497	247857	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*CDH15*	M1	<1%	1.304[0.277;6.149]	7.40E-01	2083|2|0	534534|431|0	0.0004	16:89117727	54104	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*POU5F1*	M1	<1%	0.357[0.001;166.756]	7.40E-01	1873|0|0	508507|25|0	0.00002	6:31153649:G:A	10951	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*FAM163B*	M1	<1%	0.369[0.001;163.914]	7.50E-01	1873|0|0	508499|33|0	0.00003	9:133270015:A:C	309006	21
COVID19 positive hospitalized vs COVID19 negative or unknown	*STKLD1*	M1	<1%	1.166[0.455;2.987]	7.50E-01	2080|5|0	533984|980|1	0.00092	9:133270015:A:C	106458	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*TMEM50B*	M1	<1%	0.368[0.001;185.287]	7.50E-01	1873|0|0	508494|38|0	0.00004	21:33252612:A:G	198205	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF350*	M1	<1%	0.761[0.144;4.027]	7.50E-01	2084|1|0	534690|274|1	0.00026	19:51739497	225356	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF350*	M3	<1%	0.761[0.144;4.027]	7.50E-01	2084|1|0	534690|274|1	0.00026	19:51739497	225356	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCDC94*	M3	<1%	1.203[0.364;3.973]	7.60E-01	2083|2|0	534347|617|1	0.00058	19:4719431:G:A	472285	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*DPCR1*	M1	<1%	0.823[0.237;2.860]	7.60E-01	2083|2|0	534233|731|1	0.00068	6:31153649:G:A	219027	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*DPCR1*	M3	<1%	0.823[0.237;2.860]	7.60E-01	2083|2|0	534233|731|1	0.00068	6:31153649:G:A	219027	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*DPP9*	M3	<1%	1.064[0.709;1.598]	7.60E-01	2060|25|0	528522|6430|13	0.00603	19:4719431:G:A	42868	1
COVID19 positive hospitalized vs COVID19 negative or unknown	*FPR3*	M1	<1%	0.369[0.001;215.142]	7.60E-01	1873|0|0	508510|22|0	0.00002	19:51739497	84251	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*PSORS1C1*	M1	<1%	0.898[0.453;1.780]	7.60E-01	2079|6|0	533000|1964|1	0.00184	6:31153649:G:A	24017	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*PSORS1C1*	M3	<1%	0.898[0.453;1.780]	7.60E-01	2079|6|0	533000|1964|1	0.00184	6:31153649:G:A	24017	5
COVID19 positive hospitalized vs COVID19 negative or unknown	*RNF166*	M1	<1%	1.273[0.270;6.009]	7.60E-01	2018|2|0	525477|288|0	0.00027	16:89117727	420160	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCR3*	M1	<1%	0.856[0.309;2.372]	7.70E-01	2017|3|0	525195|568|2	0.00054	3:45859597:C:T	404806	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF175*	M1	<1%	0.888[0.400;1.975]	7.70E-01	2081|4|0	533617|1345|3	0.00126	19:51739497	166168	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*ZNF175*	M3	<1%	0.888[0.400;1.975]	7.70E-01	2081|4|0	533617|1345|3	0.00126	19:51739497	166168	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*PABPN1L*	M1	<1%	0.834[0.238;2.922]	7.80E-01	2083|2|0	534369|595|1	0.00056	16:89117727	253991	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*RALGDS*	M1	<1%	1.232[0.274;5.532]	7.90E-01	2083|2|0	534634|331|0	0.00031	9:133270015:A:C	171429	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*TMEM8C*	M3	<1%	0.844[0.235;3.029]	7.90E-01	2083|2|0	534301|664|0	0.00062	9:133270015:A:C	244620	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*UBXN6*	M3	<1%	0.924[0.509;1.677]	7.90E-01	2076|8|1	532445|2517|3	0.00236	19:4719431:G:A	273934	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M1	<1%	0.805[0.146;4.438]	8.00E-01	2019|1|0	525406|359|0	0.00034	21:33252612:A:G	72443	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*NRM*	M3	<1%	0.850[0.238;3.033]	8.00E-01	2083|2|0	534283|682|0	0.00064	6:31153649:G:A	464989	33
COVID19 positive hospitalized vs COVID19 negative or unknown	*REXO4*	M3	<1%	1.097[0.527;2.285]	8.00E-01	2077|8|0	533569|1392|4	0.00131	9:133270015:A:C	136937	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*CACFD1*	M3	<1%	0.919[0.453;1.861]	8.10E-01	2080|5|0	533381|1583|1	0.00148	9:133270015:A:C	190051	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*LARS2*	M1	<1%	0.808[0.140;4.671]	8.10E-01	2004|1|0	526142|328|0	0.00031	3:45859597:C:T	465144	11
COVID19 positive hospitalized vs COVID19 negative or unknown	*PPP1R18*	M3	<1%	0.909[0.427;1.937]	8.10E-01	2079|6|0	534061|896|8	0.00085	6:31153649:G:A	476381	35
COVID19 positive hospitalized vs COVID19 negative or unknown	*PPP2R1A*	M1	<1%	0.366[0.000;1508.610]	8.10E-01	1873|0|0	508508|24|0	0.00002	19:51739497	450599	33
COVID19 positive hospitalized vs COVID19 negative or unknown	*UHRF1*	M1	<1%	0.368[0.000;1325.460]	8.10E-01	1873|0|0	508517|15|0	0.00001	19:4719431:G:A	190042	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*UHRF1*	M3	<1%	0.368[0.000;1325.460]	8.10E-01	1873|0|0	508517|15|0	0.00001	19:4719431:G:A	190042	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*CDH15*	M3	<1%	1.069[0.605;1.891]	8.20E-01	2072|13|0	532726|2233|6	0.0021	16:89117727	54104	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*MUC22*	M1	<1%	0.871[0.247;3.070]	8.30E-01	1913|2|0	425252|412|9	0.00051	6:31153649:G:A	142943	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*MUC22*	M3	<1%	0.871[0.247;3.070]	8.30E-01	1913|2|0	425252|412|9	0.00051	6:31153649:G:A	142943	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC10*	M1	<1%	1.119[0.395;3.165]	8.30E-01	1934|4|0	515732|2000|0	0.00193	19:51739497	328399	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*CPNE7*	M3	<1%	1.048[0.644;1.708]	8.50E-01	2067|18|0	530935|4030|0	0.00377	16:89117727	458170	18
COVID19 positive hospitalized vs COVID19 negative or unknown	*LTA*	M1	<1%	0.367[0.000;12959.200]	8.50E-01	1873|0|0	508522|10|0	0.00001	6:31153649:G:A	419093	24
COVID19 positive hospitalized vs COVID19 negative or unknown	*RALGDS*	M3	<1%	0.954[0.589;1.545]	8.50E-01	2069|16|0	530761|4198|6	0.00393	9:133270015:A:C	171429	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*AIF1*	M3	<1%	0.852[0.143;5.082]	8.60E-01	2084|1|0	534686|279|0	0.00026	6:31153649:G:A	461680	32
COVID19 positive hospitalized vs COVID19 negative or unknown	*PABPN1L*	M3	<1%	0.916[0.358;2.345]	8.60E-01	2081|4|0	533859|1105|1	0.00103	16:89117727	253991	7
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC5*	M3	<1%	1.036[0.692;1.549]	8.60E-01	2060|25|0	528848|6101|16	0.00573	19:51739497	127267	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*TNF*	M1	<1%	0.368[0.000;22777.100]	8.60E-01	1873|0|0	508514|18|0	0.00002	6:31153649:G:A	422092	25
COVID19 positive hospitalized vs COVID19 negative or unknown	*CACFD1*	M1	<1%	1.191[0.145;9.818]	8.70E-01	2019|1|0	525594|171|0	0.00016	9:133270015:A:C	190051	14
COVID19 positive hospitalized vs COVID19 negative or unknown	*CLDND2*	M3	<1%	0.894[0.241;3.316]	8.70E-01	2083|2|0	534613|350|2	0.00033	19:51739497	372356	27
COVID19 positive hospitalized vs COVID19 negative or unknown	*SH3GL1*	M3	<1%	0.895[0.240;3.344]	8.70E-01	2083|2|0	534346|619|0	0.00058	19:4719431:G:A	357832	17
COVID19 positive hospitalized vs COVID19 negative or unknown	*TNFAIP8L1*	M3	<1%	1.190[0.143;9.890]	8.70E-01	2019|1|0	525556|209|0	0.0002	19:4719431:G:A	67562	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*TSC1*	M1	<1%	0.912[0.307;2.703]	8.70E-01	2082|3|0	534222|743|0	0.00069	9:133270015:A:C	373781	23
COVID19 positive hospitalized vs COVID19 negative or unknown	*SFTA2*	M1	<1%	0.373[0.000;129089.000]	8.80E-01	170|0|0	109274|18|0	0.00008	6:31153649:G:A	222162	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*SFTA2*	M3	<1%	0.373[0.000;129089.000]	8.80E-01	170|0|0	109274|18|0	0.00008	6:31153649:G:A	222162	13
COVID19 positive hospitalized vs COVID19 negative or unknown	*MDC1*	M3	<1%	0.914[0.244;3.430]	8.90E-01	2083|2|0	534403|562|0	0.00053	6:31153649:G:A	453185	31
COVID19 positive hospitalized vs COVID19 negative or unknown	*VSIG10L*	M1	<1%	0.959[0.522;1.761]	8.90E-01	2078|7|0	532727|2236|2	0.00209	19:51739497	406887	30
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCHCR1*	M3	<1%	0.971[0.605;1.557]	9.00E-01	2068|17|0	530623|4332|10	0.00407	6:31153649:G:A	11058	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*GBGT1*	M1	<1%	0.968[0.588;1.596]	9.00E-01	2071|13|1	531599|3355|11	0.00316	9:133270015:A:C	116439	10
COVID19 positive hospitalized vs COVID19 negative or unknown	*TUBB*	M1	<1%	0.381[0.000;1930640.000]	9.00E-01	1873|0|0	508521|11|0	0.00001	6:31153649:G:A	433143	28
COVID19 positive hospitalized vs COVID19 negative or unknown	*TUBB*	M3	<1%	0.381[0.000;1930640.000]	9.00E-01	1873|0|0	508521|11|0	0.00001	6:31153649:G:A	433143	28
COVID19 positive hospitalized vs COVID19 negative or unknown	*MDC1*	M1	<1%	0.927[0.245;3.513]	9.10E-01	2083|2|0	534414|551|0	0.00051	6:31153649:G:A	453185	31
COVID19 positive hospitalized vs COVID19 negative or unknown	*NFKBIL1*	M3	<1%	1.132[0.140;9.129]	9.10E-01	2084|1|0	534693|272|0	0.00025	6:31153649:G:A	394045	22
COVID19 positive hospitalized vs COVID19 negative or unknown	*ADAMTS13*	M1	<1%	1.076[0.256;4.523]	9.20E-01	2083|2|0	534440|525|0	0.00049	9:133270015:A:C	152428	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*ADAMTS13*	M3	<1%	1.076[0.256;4.523]	9.20E-01	2083|2|0	534440|525|0	0.00049	9:133270015:A:C	152428	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*CBFA2T3*	M3	<1%	1.028[0.613;1.725]	9.20E-01	2070|15|0	530741|4223|1	0.00395	16:89117727	240752	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*FSD1*	M3	<1%	0.945[0.314;2.841]	9.20E-01	2082|3|0	534131|834|0	0.00078	19:4719431:G:A	414685	20
COVID19 positive hospitalized vs COVID19 negative or unknown	*SIGLEC5*	M1	<1%	1.022[0.680;1.537]	9.20E-01	2061|24|0	529067|5882|16	0.00553	19:51739497	127267	8
COVID19 positive hospitalized vs COVID19 negative or unknown	*CLDND2*	M1	<1%	1.105[0.137;8.938]	9.30E-01	1937|1|0	517548|183|1	0.00018	19:51739497	372356	27
COVID19 positive hospitalized vs COVID19 negative or unknown	*IL10RB*	M3	<1%	0.923[0.141;6.047]	9.30E-01	2017|1|0	525901|326|0	0.00031	21:33252612:A:G	13853	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*BAG6*	M1	<1%	1.057[0.137;8.174]	9.60E-01	2004|1|0	526193|274|3	0.00027	6:31153649:G:A	485481	36
COVID19 positive hospitalized vs COVID19 negative or unknown	*STKLD1*	M3	<1%	1.016[0.526;1.960]	9.60E-01	2076|9|0	533250|1713|2	0.00161	9:133270015:A:C	106458	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCHCR1*	M1	<1%	0.991[0.597;1.647]	9.70E-01	2070|15|0	531208|3748|9	0.00352	6:31153649:G:A	11058	3
COVID19 positive hospitalized vs COVID19 negative or unknown	*NUDCD2*	M1	<1%	1.039[0.135;8.008]	9.70E-01	2084|1|0	534749|216|0	0.0002	5:163300447	153519	2
COVID19 positive hospitalized vs COVID19 negative or unknown	*SPG7*	M3	<1%	1.004[0.786;1.283]	9.70E-01	2025|60|0	519685|15227|53	0.01433	16:89117727	390690	12
COVID19 positive hospitalized vs COVID19 negative or unknown	*CDSN*	M1	<1%	0.986[0.235;4.140]	9.80E-01	2076|9|0	532683|2282|0	0.00213	6:31153649:G:A	37625	6
COVID19 positive hospitalized vs COVID19 negative or unknown	*KDM4B*	M1	<1%	0.972[0.142;6.666]	9.80E-01	1939|1|0	516645|625|0	0.0006	19:4719431:G:A	313459	15
COVID19 positive hospitalized vs COVID19 negative or unknown	*NKG7*	M1	<1%	0.977[0.140;6.842]	9.80E-01	1872|1|0	508276|256|0	0.00025	19:51739497	367721	26
COVID19 positive hospitalized vs COVID19 negative or unknown	*SNAI3*	M3	<1%	1.005[0.682;1.480]	9.80E-01	2062|23|0	528564|6389|12	0.00599	16:89117727	439280	16
COVID19 positive hospitalized vs COVID19 negative or unknown	*VSIG10L*	M3	<1%	1.004[0.723;1.393]	9.80E-01	2047|38|0	524592|10351|22	0.00971	19:51739497	406887	30
COVID19 positive hospitalized vs COVID19 negative or unknown	*LRG1*	M1	<1%	0.989[0.143;6.860]	9.90E-01	2019|1|0	525547|218|0	0.00021	19:4719431:G:A	181492	9
COVID19 positive hospitalized vs COVID19 negative or unknown	*CCR1*	M3	<1%	1.001[0.234;4.283]	1.00E+00	2084|1|0	534421|543|1	0.00051	3:45859597:C:T	343648	9

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.

Supplementary Table 9. Results from burden association tests for 14 genes related to interferon signaling.

Trait	*Gene*	Burden test	MAF	Odds Ratio [95% CI]	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M1	<0.1%	0.8 (0.15, 4.44)	0.8033	2019|1|0	525406|359|0	3.41E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M1	<0.1%	2.08 (0.62, 6.96)	0.2361	2082|3|0	534277|688|0	6.43E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M1	<0.1%	0.49 (0.0, 50.22)	0.7634	1873|0|0	508491|31|10	5.00E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M1	<0.1%	0.96 (0.25, 3.64)	0.9476	2083|2|0	534559|406|0	3.80E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M1	<0.1%	1.16 (0.43, 3.18)	0.766	2082|3|0	534124|841|0	7.86E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M1	<0.1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M1	<0.1%	0.37 (0.0, 126.71)	0.7357	1873|0|0	508490|42|0	4.11E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M1	<0.1%	0.35 (0.03, 4.44)	0.4215	1873|0|0	508405|127|0	1.24E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M1	<0.1%	0.37 (0.01, 11.96)	0.5714	1873|0|0	508445|87|0	8.52E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M1	<0.1%	3.73 (0.19, 73.61)	0.387	1872|1|0	508368|164|0	1.62E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M1	<0.1%	1.13 (0.14, 8.83)	0.909	2084|1|0	534674|291|0	2.72E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M1	<0.1%	7.63 (1.87, 31.08)	0.004584	1872|0|1	508503|25|4	3.43E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M1	<0.1%	0.37 (0.0, 733.64)	0.7966	1873|0|0	508504|28|0	2.74E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M1	<0.1%	1.3 (0.27, 6.24)	0.741	1938|2|0	516861|409|0	3.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M1	<1%	0.8 (0.15, 4.44)	0.8033	2019|1|0	525406|359|0	3.41E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M1	<1%	2.08 (0.62, 6.96)	0.2361	2082|3|0	534277|688|0	6.43E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M1	<1%	0.49 (0.0, 50.22)	0.7634	1873|0|0	508491|31|10	5.00E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M1	<1%	1.82 (0.54, 6.13)	0.3334	2082|2|1	534509|455|1	4.29E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M1	<1%	1.16 (0.43, 3.18)	0.766	2082|3|0	534124|841|0	7.86E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M1	<1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M1	<1%	0.37 (0.0, 126.71)	0.7357	1873|0|0	508490|42|0	4.11E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M1	<1%	0.35 (0.03, 4.44)	0.4215	1873|0|0	508405|127|0	1.24E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M1	<1%	0.37 (0.01, 11.96)	0.5714	1873|0|0	508445|87|0	8.52E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M1	<1%	3.73 (0.19, 73.61)	0.387	1872|1|0	508368|164|0	1.62E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M1	<1%	1.13 (0.14, 8.83)	0.909	2084|1|0	534674|291|0	2.72E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M1	<1%	7.63 (1.87, 31.08)	0.004584	1872|0|1	508503|25|4	3.43E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M1	<1%	0.37 (0.0, 733.64)	0.7966	1873|0|0	508504|28|0	2.74E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M1	<1%	1.3 (0.27, 6.24)	0.741	1938|2|0	516861|409|0	3.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M1	singleton	0.37 (0.0, 44.0)	0.6857	1873|0|0	508477|55|0	5.39E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M1	singleton	0.36 (0.0, 179.42)	0.7463	1873|0|0	508500|32|0	3.13E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M1	singleton	0.55 (0.0, 2706.13)	0.8906	1873|0|0	508523|7|2	1.08E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M1	singleton	0.37 (0.0, 113.18)	0.7313	1873|0|0	508495|37|0	3.62E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M1	singleton	0.37 (0.0, 64.55)	0.7071	1873|0|0	508481|51|0	5.00E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M1	singleton	0.37 (0.0, 249.69)	0.7666	1873|0|0	508505|27|0	2.64E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M1	singleton	0.37 (0.0, 301.54)	0.7688	1873|0|0	508502|30|0	2.94E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M1	singleton	0.37 (0.0, 37.61)	0.6705	1873|0|0	508487|45|0	4.41E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M1	singleton	0.36 (0.0, 86.69)	0.7179	1873|0|0	508501|31|0	3.04E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M1	singleton	18.3 (1.71, 196.34)	0.01636	1872|1|0	508489|43|0	4.31E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M1	singleton	15.34 (1.46, 161.33)	0.02294	1939|1|0	517242|28|0	2.79E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M1	singleton	12.49 (2.71, 57.56)	0.001198	1872|0|1	508520|10|2	1.57E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M1	singleton	0.37 (0.0, 8930.06)	0.8463	1873|0|0	508514|18|0	1.76E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M1	singleton	0.37 (0.0, 186.54)	0.7539	1873|0|0	508489|43|0	4.21E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M3	<0.1%	0.76 (0.23, 2.44)	0.64	2083|2|0	534219|746|0	6.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M3	<0.1%	1.97 (0.6, 6.47)	0.2651	2082|3|0	534253|712|0	6.66E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M3	<0.1%	0.45 (0.01, 19.74)	0.6761	1873|0|0	508452|70|10	8.82E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M3	<0.1%	0.79 (0.24, 2.59)	0.692	2083|2|0	534413|552|0	5.16E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M3	<0.1%	1.14 (0.52, 2.49)	0.7481	2080|5|0	533486|1479|0	1.38E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M3	<0.1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05

COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M3	<0.1%	0.37 (0.04, 3.49)	0.3816	2018|0|0	526009|218|0	2.06E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M3	<0.1%	2.6 (1.27, 5.31)	0.008795	2073|12|0	533405|1559|1	1.46E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M3	<0.1%	1.11 (0.45, 2.79)	0.8171	2081|4|0	533861|1103|1	1.03E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	<0.1%	3.66 (0.19, 71.22)	0.392	1872|1|0	508365|167|0	1.65E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M3	<0.1%	0.81 (0.43, 1.49)	0.4921	2077|8|0	532355|2609|1	2.44E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M3	<0.1%	1.58 (0.63, 3.98)	0.3321	2001|3|1	525830|477|163	7.64E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M3	<0.1%	3.01 (0.53, 17.22)	0.2148	2019|1|0	525523|242|0	2.30E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M3	<0.1%	1.66 (0.77, 3.58)	0.1922	2075|10|0	533331|1634|0	1.53E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M3	<1%	0.76 (0.23, 2.44)	0.64	2083|2|0	534219|746|0	6.96E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M3	<1%	1.97 (0.6, 6.47)	0.2651	2082|3|0	534253|712|0	6.66E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M3	<1%	1.04 (0.54, 2.01)	0.9101	1935|0|3	516444|949|339	1.57E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M3	<1%	1.38 (0.46, 4.15)	0.5704	2082|2|1	534363|601|1	5.65E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M3	<1%	1.14 (0.52, 2.49)	0.7481	2080|5|0	533486|1479|0	1.38E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M3	<1%	0.37 (0.0, 53.77)	0.696	1873|0|0	508479|53|0	5.19E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M3	<1%	0.37 (0.04, 3.49)	0.3816	2018|0|0	526009|218|0	2.06E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M3	<1%	2.6 (1.27, 5.31)	0.008795	2073|12|0	533405|1559|1	1.46E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M3	<1%	1.11 (0.45, 2.79)	0.8171	2081|4|0	533861|1103|1	1.03E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	<1%	3.66 (0.19, 71.22)	0.392	1872|1|0	508365|167|0	1.65E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M3	<1%	0.83 (0.52, 1.32)	0.4285	2070|15|0	530068|4895|2	4.57E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M3	<1%	1.58 (0.63, 3.98)	0.3321	2001|3|1	525830|477|163	7.64E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M3	<1%	0.89 (0.48, 1.65)	0.711	2076|9|0	532255|2706|4	2.54E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M3	<1%	1.66 (0.77, 3.58)	0.1922	2075|10|0	533331|1634|0	1.53E-03
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR1*	M3	singleton	0.37 (0.01, 20.63)	0.6273	1873|0|0	508465|67|0	6.56E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IFNAR2*	M3	singleton	0.36 (0.0, 138.92)	0.7352	1873|0|0	508498|34|0	3.33E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IKBKG*	M3	singleton	0.55 (0.0, 2553.85)	0.889	1873|0|0	508522|8|2	1.18E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF3*	M3	singleton	0.37 (0.0, 46.47)	0.687	1940|0|0	517212|58|0	5.59E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF7*	M3	singleton	2.94 (0.17, 51.0)	0.4591	2004|1|0	526371|99|0	9.46E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*IRF9*	M3	singleton	0.37 (0.0, 249.69)	0.7666	1873|0|0	508505|27|0	2.64E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT1*	M3	singleton	0.37 (0.01, 19.67)	0.6207	1873|0|0	508458|74|0	7.25E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*STAT2*	M3	singleton	35.11 (4.02, 306.33)	0.001283	2018|2|0	525651|114|0	1.10E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TBK1*	M3	singleton	0.37 (0.02, 8.91)	0.5401	2005|0|0	526361|109|0	1.03E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TICAM1*	M3	singleton	17.91 (1.68, 190.85)	0.01686	1872|1|0	508486|46|0	4.60E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR3*	M3	singleton	0.93 (0.14, 6.19)	0.943	2084|1|0	534786|178|1	1.69E-04
COVID19 positive hospitalized vs COVID19 negative or unknown	*TLR7*	M3	singleton	4.02 (1.16, 13.91)	0.02818	1939|0|1	517197|55|18	8.96E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*TRAF3*	M3	singleton	0.37 (0.01, 21.93)	0.6308	1873|0|0	508461|71|0	6.96E-05
COVID19 positive hospitalized vs COVID19 negative or unknown	*UNC93B1*	M3	singleton	0.38 (0.01, 12.45)	0.5832	1953|0|0	516939|88|0	8.48E-05
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M1	<0.1%	2.62 (0.18, 38.8)	0.4837	571|1|0	516685|342|0	3.31E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M1	<0.1%	1.97 (0.17, 22.68)	0.5855	589|1|0	525553|674|0	6.41E-04
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M1	<0.1%	14.74 (1.12, 193.22)	0.04042	539|0|0	508491|31|10	5.01E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M1	<0.1%	3.02 (0.6, 15.18)	0.1793	589|1|0	525854|373|0	3.55E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M1	<0.1%	2.68 (0.39, 18.58)	0.3189	588|2|0	525395|832|0	7.92E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M1	<0.1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M1	<0.1%	0.38 (0.0, 3004.31)	0.8315	539|0|0	508490|42|0	4.13E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M1	<0.1%	0.37 (0.0, 38.82)	0.6778	539|0|0	508405|127|0	1.25E-04
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M1	<0.1%	0.38 (0.0, 211.44)	0.7619	539|0|0	508445|87|0	8.54E-05
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M1	<0.1%	0.89 (0.05, 15.25)	0.9349	539|0|0	508368|164|0	1.61E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M1	<0.1%	0.41 (0.01, 21.61)	0.6594	590|0|0	525950|277|0	2.63E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M1	<0.1%	42.12 (0.51, 3486.63)	0.0969	539|0|0	508503|25|4	3.24E-05
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M1	<0.1%	0.43 (0.0, 281622.0)	0.9011	539|0|0	508504|28|0	2.75E-05
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M1	<0.1%	3.35 (0.18, 61.63)	0.4157	538|1|0	508128|404|0	3.98E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M1	<1%	2.62 (0.18, 38.8)	0.4837	571|1|0	516685|342|0	3.31E-04

COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M1	<1%	1.97 (0.17, 22.68)	0.5855	589|1|0	525553|674|0	6.41E-04
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M1	<1%	14.74 (1.12, 193.22)	0.04042	539|0|0	508491|31|10	5.01E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M1	<1%	3.02 (0.6, 15.18)	0.1793	589|1|0	525854|373|0	3.55E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M1	<1%	2.68 (0.39, 18.58)	0.3189	588|2|0	525395|832|0	7.92E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M1	<1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M1	<1%	0.38 (0.0, 3004.31)	0.8315	539|0|0	508490|42|0	4.13E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M1	<1%	0.37 (0.0, 38.82)	0.6778	539|0|0	508405|127|0	1.25E-04
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M1	<1%	0.38 (0.0, 211.44)	0.7619	539|0|0	508445|87|0	8.54E-05
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M1	<1%	0.89 (0.05, 15.25)	0.9349	539|0|0	508368|164|0	1.61E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M1	<1%	0.41 (0.01, 21.61)	0.6594	590|0|0	525950|277|0	2.63E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M1	<1%	42.12 (0.51, 3486.63)	0.0969	539|0|0	508503|25|4	3.24E-05
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M1	<1%	0.43 (0.0, 281622.0)	0.9011	539|0|0	508504|28|0	2.75E-05
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M1	<1%	3.35 (0.18, 61.63)	0.4157	538|1|0	508128|404|0	3.98E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M1	singleton	0.37 (0.0, 165.53)	0.7518	539|0|0	508477|55|0	5.40E-05
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M1	singleton	0.48 (0.0, 901579.0)	0.9216	539|0|0	508500|32|0	3.14E-05
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M1	singleton	0.58 (0.0, 711727.0)	0.939	490|0|0	399233|6|1	1.00E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M1	singleton	24.01 (0.35, 1669.95)	0.1419	539|0|0	508495|37|0	3.63E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M1	singleton	0.45 (0.0, 19828.4)	0.8843	539|0|0	508481|51|0	5.01E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M1	singleton	0.45 (0.0, 564343.0)	0.9115	539|0|0	508505|27|0	2.65E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M1	singleton	0.38 (0.0, 9818.87)	0.8505	539|0|0	508502|30|0	2.95E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M1	singleton	0.39 (0.0, 13826.4)	0.861	539|0|0	508487|45|0	4.42E-05
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M1	singleton	0.38 (0.0, 28255.6)	0.8649	539|0|0	508501|31|0	3.04E-05
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M1	singleton	15.49 (0.28, 860.18)	0.1812	539|0|0	508489|43|0	4.22E-05
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M1	singleton	0.38 (0.0, 18335.2)	0.8602	539|0|0	508509|23|0	2.26E-05
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M1	singleton	0.4 (0.0, 3891300000.0)	0.9371	490|0|0	399229|9|2	1.63E-05
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M1	singleton	0.42 (0.0, 1871470.0)	0.9114	539|0|0	508514|18|0	1.77E-05
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M1	singleton	0.42 (0.0, 20393.0)	0.8758	539|0|0	508489|43|0	4.22E-05
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M3	<0.1%	1.07 (0.15, 7.68)	0.9458	589|1|0	525500|727|0	6.91E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M3	<0.1%	1.88 (0.17, 20.82)	0.6068	589|1|0	525529|698|0	6.63E-04
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M3	<0.1%	12.55 (0.99, 159.28)	0.051	539|0|0	508452|70|10	8.84E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M3	<0.1%	2.53 (0.54, 11.8)	0.2388	589|1|0	525713|514|0	4.89E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M3	<0.1%	3.07 (0.81, 11.64)	0.09817	587|3|0	524764|1463|0	1.39E-03
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M3	<0.1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M3	<0.1%	0.38 (0.01, 14.6)	0.6027	590|0|0	526009|218|0	2.07E-04
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M3	<0.1%	1.64 (0.36, 7.55)	0.5246	587|3|0	524718|1508|1	1.44E-03
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M3	<0.1%	1.96 (0.33, 11.47)	0.456	588|2|0	525137|1089|1	1.04E-03
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M3	<0.1%	0.89 (0.05, 15.22)	0.9349	539|0|0	508365|167|0	1.64E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M3	<0.1%	0.74 (0.24, 2.26)	0.5951	588|2|0	523680|2546|1	2.42E-03
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M3	<0.1%	1.22 (0.29, 5.15)	0.7855	557|0|0	517105|467|160	7.59E-04
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M3	<0.1%	14.61 (1.54, 138.27)	0.01935	571|1|0	516792|235|0	2.28E-04
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M3	<0.1%	3.13 (1.26, 7.77)	0.01414	584|6|0	524612|1615|0	1.54E-03
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M3	<1%	1.07 (0.15, 7.68)	0.9458	589|1|0	525500|727|0	6.91E-04
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M3	<1%	1.88 (0.17, 20.82)	0.6068	589|1|0	525529|698|0	6.63E-04
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M3	<1%	1.41 (0.48, 4.17)	0.5303	556|0|1	516444|949|339	1.57E-03
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M3	<1%	2.53 (0.54, 11.8)	0.2388	589|1|0	525713|514|0	4.89E-04
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M3	<1%	3.07 (0.81, 11.64)	0.09817	587|3|0	524764|1463|0	1.39E-03
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M3	<1%	0.42 (0.0, 5297.95)	0.8575	539|0|0	508479|53|0	5.21E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M3	<1%	0.38 (0.01, 14.6)	0.6027	590|0|0	526009|218|0	2.07E-04
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M3	<1%	1.64 (0.36, 7.55)	0.5246	587|3|0	524718|1508|1	1.44E-03
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M3	<1%	1.96 (0.33, 11.47)	0.456	588|2|0	525137|1089|1	1.04E-03
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M3	<1%	0.89 (0.05, 15.22)	0.9349	539|0|0	508365|167|0	1.64E-04

COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M3	<1%	0.97 (0.41, 2.26)	0.9396	585|5|0	521403|4822|2	4.59E-03
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M3	<1%	1.22 (0.29, 5.15)	0.7855	557|0|0	517105|467|160	7.59E-04
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M3	<1%	1.27 (0.49, 3.25)	0.6217	587|3|0	523530|2693|4	2.57E-03
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M3	<1%	3.13 (1.26, 7.77)	0.01414	584|6|0	524612|1615|0	1.54E-03
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR1*	M3	singleton	0.37 (0.0, 119.72)	0.738	539|0|0	508465|67|0	6.58E-05
COVID19 positive severe vs COVID19 negative or unknown	*IFNAR2*	M3	singleton	0.47 (0.0, 448932.0)	0.9144	539|0|0	508498|34|0	3.34E-05
COVID19 positive severe vs COVID19 negative or unknown	*IKBKG*	M3	singleton	0.57 (0.0, 614503.0)	0.9374	490|0|0	399232|7|1	1.13E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF3*	M3	singleton	20.95 (0.32, 1352.58)	0.1525	539|0|0	508480|52|0	5.11E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF7*	M3	singleton	0.42 (0.0, 600.62)	0.8166	557|0|0	517640|92|0	8.88E-05
COVID19 positive severe vs COVID19 negative or unknown	*IRF9*	M3	singleton	0.45 (0.0, 564343.0)	0.9115	539|0|0	508505|27|0	2.65E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT1*	M3	singleton	0.38 (0.0, 269.14)	0.7735	539|0|0	508458|74|0	7.27E-05
COVID19 positive severe vs COVID19 negative or unknown	*STAT2*	M3	singleton	0.4 (0.0, 128.93)	0.7543	572|0|0	516919|108|0	1.04E-04
COVID19 positive severe vs COVID19 negative or unknown	*TBK1*	M3	singleton	0.38 (0.0, 184.6)	0.7614	557|0|0	517628|104|0	1.00E-04
COVID19 positive severe vs COVID19 negative or unknown	*TICAM1*	M3	singleton	15.0 (0.27, 819.65)	0.1846	539|0|0	508486|46|0	4.52E-05
COVID19 positive severe vs COVID19 negative or unknown	*TLR3*	M3	singleton	0.41 (0.01, 15.67)	0.6287	590|0|0	526065|161|1	1.55E-04
COVID19 positive severe vs COVID19 negative or unknown	*TLR7*	M3	singleton	11.63 (0.84, 161.65)	0.06761	539|0|0	508468|49|15	7.76E-05
COVID19 positive severe vs COVID19 negative or unknown	*TRAF3*	M3	singleton	0.4 (0.0, 689.93)	0.8098	539|0|0	508461|71|0	6.97E-05
COVID19 positive severe vs COVID19 negative or unknown	*UNC93B1*	M3	singleton	0.42 (0.0, 250.75)	0.7916	572|0|0	516939|88|0	8.50E-05

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.

Supplementary Table 10. Results from burden association tests for 32 additional genes of biological or therapeutic interest.

Trait	Gene	Burden test	MAF	Odds Ratio [95% CI]	P-value	N cases with RR|RA|AA genotype*	N controls with RR|RA|AA genotype*	AAF
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23R	M1	<1%	3.849[0.853;17.373]	8.00E-02	1871|2|0	508324|208|0	0.00021
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1A	M3	<1%	2.350[0.835;6.611]	1.10E-01	2016|4|0	525349|415|1	0.0004
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL3	M1	<1%	14.959[0.345;647.891]	1.60E-01	1872|1|0	508438|94|0	0.00009
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1A	M1	<1%	4.218[0.574;31.008]	1.60E-01	2019|1|0	525641|124|0	0.00012
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL1	M3	<1%	0.369[0.086;1.585]	1.80E-01	2085|0|0	534569|395|1	0.00037
COVID19 positive hospitalized vs COVID19 negative or unknown	TMPRSS2	M1	<1%	2.526[0.646,9.876]	1.80E-01	1936|4|0	516764|506|0	0.00049
COVID19 positive hospitalized vs COVID19 negative or unknown	C5	M1	<1%	2.077[0.702;6.144]	1.90E-01	2081|4|0	534324|640|1	0.0006
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL1	M1	<1%	0.369[0.081;1.687]	2.00E-01	2085|0|0	534607|357|1	0.00033
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RC	M3	<1%	1.643[0.749;3.604]	2.20E-01	2080|5|0	533824|1140|1	0.00107
COVID19 positive hospitalized vs COVID19 negative or unknown	VEGFA	M3	<1%	0.558[0.219;1.418]	2.20E-01	2083|2|0	533873|1091|1	0.00102
COVID19 positive hospitalized vs COVID19 negative or unknown	IL7R	M1	<1%	1.668[0.692;4.019]	2.50E-01	2079|6|0	533848|1117|0	0.00105
COVID19 positive hospitalized vs COVID19 negative or unknown	IL12B	M3	<1%	2.200[0.438;11.048]	3.40E-01	2017|1|0	526033|194|0	0.00018
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23A	M3	<1%	0.366[0.046;2.919]	3.40E-01	1938|0|0	517449|282|1	0.00027
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RA	M1	<1%	0.359[0.040;3.220]	3.60E-01	2020|0|0	525537|228|0	0.00022
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNLR1	M3	<1%	0.366[0.040;3.321]	3.70E-01	1938|0|0	517531|201|0	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1B	M3	<1%	0.369[0.039;3.491]	3.80E-01	2005|0|0	526208|262|0	0.00025
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL3	M3	<1%	3.464[0.185;64.982]	4.10E-01	1939|1|0	517141|129|0	0.00013
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK1	M1	<1%	1.942[0.398;9.474]	4.10E-01	1937|1|0	517541|189|2	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK1	M3	<1%	1.942[0.398;9.474]	4.10E-01	1937|1|0	517541|189|2	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNLR1	M1	<1%	0.365[0.030;4.527]	4.30E-01	1938|0|0	517571|161|0	0.00015
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1B	M1	<1%	0.368[0.030;4.481]	4.30E-01	1873|0|0	508320|212|0	0.00021
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK2	M1	<1%	0.366[0.029;4.555]	4.30E-01	1938|0|0	517530|202|0	0.00019
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23R	M3	<1%	0.847[0.554;1.296]	4.40E-01	2067|18|0	529085|5861|19	0.00551
COVID19 positive hospitalized vs COVID19 negative or unknown	VEGFA	M1	<1%	0.661[0.218;2.002]	4.60E-01	2083|2|0	534217|747|1	0.0007
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1R1	M1	<1%	0.666[0.222;1.995]	4.70E-01	1936|2|0	517281|444|7	0.00044
COVID19 positive hospitalized vs COVID19 negative or unknown	IL7R	M3	<1%	1.269[0.666;2.419]	4.70E-01	2075|10|0	532768|2197|0	0.00205
COVID19 positive hospitalized vs COVID19 negative or unknown	TMPRSS2	M3	<1%	1.341[0.606,2.967]	4.70E-01	2077|8|0	533498|1467|0	0.00137
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNG	M3	<1%	0.366[0.020;6.537]	4.90E-01	1873|0|0	508402|130|0	0.00013
COVID19 positive hospitalized vs COVID19 negative or unknown	BTK	M3	<1%	0.497[0.061;4.077]	5.10E-01	2020|0|0	525622|114|29	0.00016
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6	M3	<1%	0.369[0.019;7.067]	5.10E-01	1953|0|0	516905|122|0	0.00012
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6R	M1	<1%	0.377[0.020;7.210]	5.20E-01	1940|0|0	517152|118|0	0.00011
COVID19 positive hospitalized vs COVID19 negative or unknown	IL12B	M1	<1%	0.365[0.016;8.562]	5.30E-01	1873|0|0	508442|90|0	0.00009
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1R1	M3	<1%	0.739[0.283;1.931]	5.40E-01	2082|3|0	534274|684|7	0.00065
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6	M1	<1%	0.367[0.014;9.615]	5.50E-01	1873|0|0	508423|109|0	0.00011
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNGR1	M3	<1%	0.651[0.149;2.841]	5.70E-01	2084|1|0	534532|433|0	0.0004
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL2	M3	<1%	1.481[0.380;5.766]	5.70E-01	2082|3|0	534408|557|0	0.00052
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNB1	M3	<1%	0.828[0.423;1.623]	5.80E-01	2011|7|0	524038|2186|3	0.00208
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNG	M1	<1%	0.364[0.011;12.464]	5.80E-01	1873|0|0	508453|79|0	0.00008
COVID19 positive hospitalized vs COVID19 negative or unknown	JAK2	M3	<1%	0.850[0.481;1.503]	5.80E-01	2075|10|0	532245|2714|6	0.00255
COVID19 positive hospitalized vs COVID19 negative or unknown	IL4R	M1	<1%	1.931[0.154;24.219]	6.10E-01	1937|1|0	517553|179|0	0.00017
COVID19 positive hospitalized vs COVID19 negative or unknown	PDCD1	M3	<1%	0.367[0.005;29.373]	6.50E-01	1873|0|0	508473|59|0	0.00006
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17A	M1	<1%	0.364[0.004;35.613]	6.70E-01	1873|0|0	508492|40|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	IL23A	M1	<1%	0.365[0.002;57.511]	7.00E-01	1873|0|0	508494|38|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	ACE2	M1	<1%	0.392[0.002;61.868]	7.20E-01	1873|0|0	508485|44|3	0.00005
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1RAP	M3	<1%	1.272[0.349;4.641]	7.20E-01	2083|2|0	534386|579|0	0.00054
COVID19 positive hospitalized vs COVID19 negative or unknown	IL4R	M3	<1%	1.534[0.147;16.057]	7.20E-01	2017|1|0	526039|188|0	0.00018
COVID19 positive hospitalized vs COVID19 negative or unknown	PDCD1	M1	<1%	0.367[0.002;83.673]	7.20E-01	1873|0|0	508492|40|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	CSF2	M3	<1%	0.368[0.001;136.635]	7.40E-01	1873|0|0	508491|41|0	0.00004
COVID19 positive hospitalized vs COVID19 negative or unknown	BTK	M1	<1%	0.363[0.001;230.098]	7.60E-01	1873|0|0	508505|27|0	0.00003
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNGR1	M1	<1%	0.807[0.145;4.481]	8.10E-01	2084|1|0	534629|336|0	0.00031

COVID19 positive hospitalized vs COVID19 negative or unknown	ACE2	M3	<1%	0.944[0.582;1.533]	8.20E-01	2079|2|4	532861|1626|478	0.00241
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR5	M1	<1%	0.939[0.521;1.690]	8.30E-01	2077|8|0	532508|2453|4	0.0023
COVID19 positive hospitalized vs COVID19 negative or unknown	CCR5	M3	<1%	0.939[0.521;1.690]	8.30E-01	2077|8|0	532508|2453|4	0.0023
COVID19 positive hospitalized vs COVID19 negative or unknown	IL1RAP	M1	<1%	1.281[0.142;11.540]	8.30E-01	1872|1|0	508333|199|0	0.0002
COVID19 positive hospitalized vs COVID19 negative or unknown	CSF2	M1	<1%	0.370[0.000;6631.170]	8.40E-01	1873|0|0	508515|17|0	0.00002
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RC	M1	<1%	1.113[0.317;3.899]	8.70E-01	2083|2|0	534378|587|0	0.00055
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17A	M3	<1%	0.885[0.140;5.608]	9.00E-01	1872|1|0	508249|283|0	0.00028
COVID19 positive hospitalized vs COVID19 negative or unknown	C5	M3	<1%	0.984[0.670;1.445]	9.30E-01	2059|26|0	529016|5928|21	0.00558
COVID19 positive hospitalized vs COVID19 negative or unknown	IL6R	M3	<1%	1.089[0.143;8.291]	9.30E-01	2084|1|0	534746|219|0	0.0002
COVID19 positive hospitalized vs COVID19 negative or unknown	IL17RA	M3	<1%	1.009[0.713;1.429]	9.60E-01	2052|33|0	527528|7417|20	0.00697
COVID19 positive hospitalized vs COVID19 negative or unknown	IL33	M3	<1%	0.988[0.649;1.505]	9.60E-01	2063|22|0	529239|5720|6	0.00536
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNB1	M1	<1%	0.987[0.470;2.070]	9.70E-01	1946|7|0	515284|1741|2	0.00169
COVID19 positive hospitalized vs COVID19 negative or unknown	IL33	M1	<1%	0.993[0.652;1.513]	9.70E-01	2063|22|0	529265|5694|6	0.00533
COVID19 positive hospitalized vs COVID19 negative or unknown	IFNL2	M1	<1%	0.992[0.240;4.100]	9.90E-01	2083|2|0	534469|496|0	0.00046

* RR: individuals who have genotype Reference/Reference for all variants included in burden test. RA: individuals who have genotype Reference/Alternate for at least one variant. AA: individuals who have genotype Alternate/Alternate for at least one variant.